Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
Conjugating pneumococcal capsular polysaccharides to carrier proteins through covalent or non-covalent methods addresses the challenge of immunological memory induction, enhancing vaccine efficacy by converting independent T antigens into dependent T antigens.
Patent Information
- Application Number
- SA1120262007
- Authority / Receiving Office
- SA · SA
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-03-12
- Publication Date
- 2026-10-05
AI Technical Summary
Existing vaccines using pneumococcal capsular polysaccharides as standalone antigens do not effectively induce immunological memory, particularly in children, necessitating improved methods to enhance their immunoreactivity and efficacy.
Conjugation of pneumococcal capsular polysaccharides to carrier proteins via covalent or non-covalent bonds, specifically using rhizavidin/biotin systems or chemical activation with agents like CDI and CDT, to convert independent T antigens into dependent T antigens, thereby stimulating immunological memory.
The conjugation process enhances the immunoreactivity of pneumococcal polysaccharides, effectively inducing antibody responses and improving vaccine efficacy, particularly in childhood immunization.
Smart Images

Figure 46CCE7DB-1C98-448F-B0C7-6E70D27112AE 
Figure 667BD2F1-7673-43EE-8416-2660AF3CA5BB 
Figure 7E12B30E-10A2-48E6-B05A-233EF5C82196
Abstract
Description
The present invention is directed in part to pneumococcal capsular polysaccharide antigens (also called glycosides). For the purpose of the invention, the term "glycosidic conjugate" refers to a pneumococcal capsular polysaccharide conjugated to a carrier protein via covalent or non-covalent bonds. In one embodiment, the pneumococcal capsular polysaccharide is conjugated to a carrier protein via non-covalent bonds (such as the rhizavidin / biotin system; see, for example, WO2012155007 and WO2020056202). Preferably, the capsular polysaccharide is conjugated via covalent bonds. In one embodiment, the capsular polysaccharide is conjugated directly to a carrier protein. In a second embodiment, the capsular polysaccharide is conjugated to a carrier protein via a spacer / ligand. Pneumococcal capsule polysaccharides specific to the invention. The term "saccharide" throughout this specification may refer to a polysaccharide or an oligosaccharide, and includes both. In an embodiment, the saccharides of the invention may be oligosaccharides. Oligosaccharides have a smaller number of repeat units (typically 5–15) and are usually derived synthetically or by hydrolysis of polysaccharides. However, it is preferable that all saccharides in the present invention and in the immunomodulatory formulations of the present invention be polysaccharides. High molecular weight polysaccharides are capable of inducing certain antibody immune responses due to the presence of epitopes on the antigenic surface. It is preferable that high molecular weight capsule polysaccharides be isolated and purified for use in the conjugates, formulations, and methods of the present invention. Therefore, in a preferred embodiment of the present invention, the saccharide is a polysaccharide. Preferably, the saccharides used in the present invention are capsular saccharides of pneumococci (also called "capsular saccharide of Streptococcus pneumoniae" or "capsular saccharide" herein). Capsules are found in many bacteria of medical interest. Bacterial capsules are composed largely of polysaccharides. The capsular saccharides are prepared by standard techniques known to those skilled in the art of manufacturing. In one embodiment, the capsular polysaccharides of Streptococcus pneumoniae used in the present invention are synthetic carbohydrates. However, in a preferred embodiment, the source of capsular polysaccharides from Streptococcus pneumoniae, according to this invention, may be Streptococcus pneumoniae cells. Streptococcus pneumoniae strains that can be used as a source of capsular polysaccharides may be obtained from approved culture collections (e.g., the American Type Culture Collection (ATCC, Manassas, VA, USA) or a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Capsular polysaccharides can be directly obtained from Streptococcus pneumoniae bacteria using isolation procedures known to a layperson in the art of synthesis (see, for example, the methods described in US2006 / 0228380, US2006 / 0228381, US2007 / 0184071, US2007 / 0184072, US2007 / 0231340, US2008 / 0102498, and WO2008 / 118752). They can also be produced using synthetic protocols known to a layperson in the art of synthesis. When capsular polysaccharides are obtained directly from Streptococcus pneumoniae bacteria, the bacterial cells can be grown in a medium (e.g., soy-based). Following fermentation, the bacterial cells can be lysed to produce cell lysate. The capsular polysaccharide can then be isolated from the cell lysate using purification techniques well-established in the field, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, and WO2008 / 118752). The purified capsular polysaccharide can then be used to prepare immunogenic conjugates. The resulting isolated capsule polysaccharide can be characterized by purification using various parameters, including, for example, molecular weight (Mw). The molecular weight of the polysaccharide can be determined using size exclusion chromatography (SEC) combined with a multiangle laser light scattering detector (MALLS). The capsular polysaccharides used in the present invention are capsular polysaccharides of Streptococcus pneumoniae. Preferably, the capsular polysaccharide used in the present invention shall be capsular polysaccharides of Streptococcus pneumoniae serotypes selected from serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9V, 9N, 10A, 10B, 10C, 10F, 11A, 11B, 11C, 11D, 11E, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 18A, 18B. 18C, 18F, 19A, 19B, 19C, 19F, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31, 32A, 32F, 33A, 33B, 33C, 33D, 33E, 33F, 34, 35A, 35B, 35C, 35F, 36, 37, 38, 39, 40, 41A, 41F, 42, 43, 44, 45, 46, 47A, 47F and 48. Preferably, the capsular polysaccharides used in the present invention shall be capsular polysaccharides of Streptococcus pneumoniae serotypes selected from serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 7C, 7F, 8, 9V, 9N, 10A, 10B, 11A, 12F, 14, 15A, 15B, 15C, 16F, 17F, 18C, 19A, 19F, 20A, 20B, 21, 22A, 22F, 23A, 23B, 23F, 24B, 24F, 27, 29, 31, 33B, 33F, 34, 35B, 35F, 38 72 and 73. The capsular polysaccharides of Streptococcus pneumoniae include repeating oligosaccharide units which may contain up to 8 sugar residues. In one incarnation, the capsular polysaccharide of the invention could be a single oligosaccharide unit, or a polysaccharide chain shorter than the original length of repeating oligosaccharide units. In another incarnation, the capsular polysaccharide of the invention is a single repeating oligosaccharide unit of a related serotype. In one incarnation, the encapsulated saccharides of the invention may be oligosaccharides. Oligosaccharides have a smaller number of repeat units (typically 5–15) and are usually derived synthetically or by hydrolysis of polysaccharides. In a preferred embodiment, the encapsulated polysaccharides of the present invention are high molecular weight polysaccharides. These polysaccharides are capable of inducing certain antibody immune responses due to the presence of epitopes on the antigenic surface. It is preferable to isolate and purify these high molecular weight encapsulated polysaccharides for use in the conjugates, formulations, and methods described in the present invention. In a preferred embodiment, the isolated capsular polysaccharides used in the present invention (purified prior to further processing) have an average molecular weight between 50 kDa and 5000 kDa. In a preferred embodiment, the capsular polysaccharide used in the present invention has an average molecular weight between 200 kDa and 4000 kDa. Any whole number within any of the ranges mentioned above is considered an embodiment of the disclosure. The invention-specific properties of glycoconjugates of Streptococcus pneumoniae generally involve the conjugation of polysaccharides to carriers, which enhances polysaccharide immunoreactivity by converting them from independent T antigens to dependent T antigens, thereby stimulating immunological memory. Conjugation is particularly beneficial in childhood vaccines. The isolated capsular polysaccharides described above can be activated (e.g., chemically activated) to make them capable of reacting (e.g., with a linker or directly with the carrier protein) and then incorporated into glycosides, as further described here. Prior to activation, the size of isolated polysaccharides can be reduced while preserving the essential features of polysaccharide structure. Mechanical or chemical sizing can be used. In one embodiment, the size of the isolated polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis can be performed using a dilute acid (e.g., acetic acid, formic acid, propanoic acid). In one embodiment, chemical hydrolysis is performed using formic acid. In another embodiment, chemical hydrolysis is performed using propanoic acid. In a preferred embodiment, chemical hydrolysis is performed using acetic acid. Chemical hydrolysis can also be performed using a dilute strong acid (e.g., dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid, or dilute perchloric acid). In one embodiment, chemical hydrolysis is performed using dilute hydrochloric acid.In one incarnation, chemical hydrolysis is performed using dilute sulfuric acid. In another incarnation, chemical hydrolysis is performed using dilute phosphoric acid. In yet another incarnation, chemical hydrolysis is performed using dilute nitric acid. In another incarnation, chemical hydrolysis is performed using dilute perchloric acid. The size of the isolated polysaccharide can also be reduced by mechanical homogenization. In one application, the size of the isolated polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process current through a sufficiently small flow path. Shear rates are increased by applying a large homogenization pressure, and exposure time can be extended by recirculating the feed current through the homogenizer. The average molecular weight (Mw) of a polysaccharide before conjugation refers to the molecular weight before the polysaccharide is activated (i.e., after a final sizing step but before the polysaccharide reacts with an activating agent). In the context of the present invention, the molecular weight of the polysaccharide is not substantially altered by the activation step, and the molecular weight of the polysaccharide included in the conjugate is identical to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the pneumococcal glycoconjugates of the present invention include capsular polysaccharides of Streptococcus pneumoniae where the average molecular weights (Mw) of the said polysaccharides prior to conjugation range between 50 kDa and 1,000 kDa. In one embodiment, the pneumococcal glycoconjugates of the present invention include capsular polysaccharides of Streptococcus pneumoniae where the average molecular weights (Mw) of said polysaccharides prior to conjugation range between 50 kDa and 600 kDa. In one embodiment, the pneumococcal glycoconjugates of the present invention include capsular polysaccharides of Streptococcus pneumoniae where the average molecular weights (Mw) of said polysaccharides prior to conjugation range between 50 kDa and 500 kDa. In some embodiments, the pneumococcal glycosides of the invention have an average molecular weight (Mw) between 250 kDa and 20,000 kDa. In some incarnations, the pneumococcal glycoconjugates of the invention have an average molecular weight (Mw) between 500 kDa and 15,000 kDa. Another method for distinguishing the pneumococcal glycoconjugates of the invention is by the number of lysine residues in the carrier protein (e.g., CRM197, SCP, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a range of conjugated lysines (degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds of the polysaccharide, can be obtained by amino acid analysis using routine methods known to those skilled in the art of synthesis. Conjugation may reduce the number of recovered lysine residues compared to the carrier protein precursor used to produce the conjugate material. In a preferred embodiment, the degree of conjugation of the pneumococcal glycoconjugates of the invention ranges from 2 to 15. The pneumococcal glycoconjugates of the invention can also be distinguished by the ratio (w / w) of saccharide to carrier protein. In some incarnations, the ratio of capsular saccharides of pneumococcal to carrier protein in the glycoconjugate (w / w) ranges from 0.5 to 3.0. In other incarnations, the ratio ranges from 0.5 to 2.0. In yet other incarnations, the ratio ranges from 0.5 to 1.5. In still others, the ratio ranges from 0.5 to 1.2. In yet others, the ratio ranges from 0.5 to 1.0. In still others, the ratio ranges from 1.0 to 1.5. In other incarnations, the ratio of saccharide to carrier protein (w / w) ranges between 1.0 and 2.0. In additional incarnations, the ratio of saccharide to carrier protein (w / w) ranges between 0.8 and 1.2. Pneumococcal glycosides and invention-specific formulations may contain a free polysaccharide that is not conjugated to the carrier protein but is instead present in the glycosidic formulation. The free polysaccharide may be non-covalently bound to the glycosidic conjugate (i.e., non-covalently attached to it, adsorbed with it, or drawn into or with it). In a preferred embodiment, each invention-specific pneumococcal glycosidic conjugate contains approximately 50% less free pneumococcal polysaccharide compared to the total amount of polysaccharide. In another preferred embodiment, each invention-specific pneumococcal glycosidic conjugate contains approximately 25% less free pneumococcal polysaccharide compared to the total amount of polysaccharide. Glycoplasma conjugates can also be distinguished from Streptococcus pneumoniae by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Large molecules are excluded from the pores in the media and exit more rapidly than small molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In a preferred embodiment, at least 30% of the pneumococcal glycosurfactant Kd of the invention has a value less than or equal to 0.3 in column CL-4B. In a preferred embodiment, at least 40% of the pneumococcal glycosurfactant Kd has a value less than or equal to 0.3 in column CL-4B. In a preferred embodiment, between 40% and 80% of the pneumococcal glycosurfactant Kd of the invention has a value less than or equal to 0.3 in column CL-4B. The method of preparing the glycoconjugates from Streptococcus pneumoniae specific to the invention: The glycoconjugates from Streptococcus pneumoniae specific to the present invention may be prepared by any conjugation technique known to those skilled in the art of manufacturing. In one incarnation, the capsular polysaccharide of Streptococcus pneumoniae is coupled to the carrier protein via non-covalent bonds (see, for example, WO2012155007, WO2020056202). In one incarnation, the capsular polysaccharide from Streptococcus pneumoniae is covalently linked. In another incarnation, the capsular polysaccharide is directly linked to a carrier protein. In a second incarnation, the capsular polysaccharide is linked to a carrier protein via a spacer / ligand. In one embodiment, some or all of the glycosides of the pneumococci of the present invention are linked to the carrier protein via a ligand, for example, a bifunctional ligand. The ligand is selectively heterofunctional or homofunctional, having, for example, one reactive amino group and one reactive carboxylic acid group, two reactive amino groups, or two reactive carboxylic acid groups. The ligand has, for example, between 4 and 20, 4 and 12, and 5 and 10 carbon atoms. A possible linker is adipic acid dihydrazide (ADH). Other linkers include β-propionamido (WO 00 / 10599), nitrophenyl-ethylamine (Gever et al (1979) Med. Microbiol. lmmunol. 165; 171-288), haloalkyl halides (US4057685), glycosidic links (US4673574, US4808700), hexanediamine, and 6-aminocaproic acid (US4459286). In one embodiment, some or all of the glycosylated conjugates of the pneumococci of the present invention are directly coupled to the carrier protein (without a linker). In general, the following types of chemical groups can be used on a protein carrier for conjugation / coupling: (1) An amino group (e.g., via lysine). In one embodiment, this group is attached to carboxyl groups on polysaccharides directly or to a carboxyl group on a bond using carbodiimide chemistry, e.g., using EDAC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide). In another embodiment, this group is attached to CDAP- or CNBr-activated carboxyl groups on polysaccharides directly or to such groups on a bond; to polysaccharides or bonds containing an aldehyde group; to polysaccharides or bonds containing a succinimide ester group. (2) Carboxyl group (e.g., via aspartic acid or glutamic acid). In one embodiment, this group is linked to amino groups on the polysaccharides directly or to an amino group on a bond using carbomer chemistry, e.g., using EDAC. (3) Sulfhydryl (e.g., via cysteine). In one incarnation, this group is linked to a bromo- or chloro-acetylated ligand or polysaccharide using maleimide chemistry. In another incarnation, this group is activated / modified using bisdiazobenzidine. (4) Hydroxyl group (e.g., via tyrosine). In one incarnation, this group is activated / modified using diazobenzidine. (5) The imidazolyl group (e.g., via histidine). In one incarnation, this group is activated / modified using diazobenzidine. (6) Guanidyl group (for example, via arginine). (7) Indolyl group (e.g., via tryptophan). On pneumococcal polysaccharides, the following groups can generally be used for conjugation: OH, COOH or NH2. Aldehyde groups can be created after various treatments known in the art of industry such as: periodate pyrolysis, acid hydrolysis, hydrogen peroxide, etc. In one embodiment, some or all of the glycosides from the pneumococcal strain of the present invention are prepared using CDAP chemistry. In this embodiment, the pneumococcal polysaccharide is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide can then be conjugated directly or via a spacer group (linker) to an amino group on the carrier protein.For example, the spacer could be cystamine to give a thiolated polysaccharide that can be conjugated to the carrier via a thioether bond formed after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (e.g., using iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl (4-Iodoacetyl)aminobenzoate sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP). In a preferred embodiment, the cyanate ester of the activated polysaccharide is conjugated to either amine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein using carbodime chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. In one embodiment, part or all of the glycoconjugates of the pneumococci specific to the present invention are prepared using carbomides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Several of these are described in International Patent Application Publication No. WO 98 / 42721. The conjugation may involve a carbonyl linkage, which may be formed by the reaction of a free hydroxyl group of the saccharide with CDI (see Bethell et al. (1979) 1. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518) followed by a reaction with a protein to form a carbamate linkage. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form an intermediate CDI carbamate complex, and the association of the intermediate CDI carbamate complex with an amino group present on a protein. Direct reducing amino acids In one embodiment, part or all of the glycoconjugates of the pneumococcal species of the present invention are prepared by direct amine reduction (see, for example, US 4365170, US 4673574, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). According to the present invention, the amine reduction involves two steps: (1) oxidation (activation) of purified pneumococcal polysaccharide, and (2) reduction of the activated polysaccharide and carrier protein (e.g., CRM197, TT, or SCP) to form a glycoconjugate. As mentioned above, prior to oxidation, the polysaccharide from Streptococcus pneumoniae can be sized to a target molecular weight (MW) range. Therefore, in one of the incarnations, the size of the isolated polysaccharide is determined prior to oxidation. In one embodiment, the pneumococcal polysaccharide of the invention is coupled to a carrier protein through a process that includes the following steps: (a) The reaction of the polysaccharide from the aforementioned pneumococci with an oxidizing agent; (b) Synthesis of the activating polysaccharide from step (a) with a carrier protein; and (c) The activated polysaccharide complex and the carrier protein react with a reducing agent to form a glycoconjugate. In one embodiment, the pneumococcal polysaccharide of the invention is linked to a carrier protein through a process that includes the following steps: (a) The reaction of the polysaccharide from the aforementioned pneumococci with an oxidizing agent; (a) Quenching the oxidation reaction by adding a reducing agent; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) The activated polysaccharide complex and the carrier protein react with a reducing agent to form a glycoconjugate. After the oxidation step (a), it is noted that the saccharide is activated and referred to as an "activated saccharide". In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate periodate" includes both pyrodate and periodic acid; the term also includes metaperiodate (IO4-), orthoperiodate (IO65-), and various salts of pyrodate (for example, sodium periodate and potassium periodate). In one embodiment, the oxidizing agent is a pyrodate in the presence of divalent cations (see WO2008 / 143709). In one incarnation, the oxidizing agent is pyridic acid. In another incarnation, the oxidizing agent is pyridic acid in the presence of divalent cations. In yet another incarnation, the oxidizing agent is pyridic acid in the presence of Mg2+. In another incarnation, the oxidizing agent is pyridic acid in the presence of Ca2+. In another incarnation, the oxidizing agent is orthopyridates. In one incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with a pyridate, the pyridate oxidizes the adjacent hydroxyl groups to form carbonyl or aldehyde groups and causes the CC bond to cleavage. For this reason, the term "reacting a polysaccharide with a pyridate" implies the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.01–2 molar equivalents of pyridates. In another embodiment, step (a) involves the reaction of the polysaccharide with 0.1–1.0 molar equivalents of pyridates. In yet another embodiment, step (a) involves the reaction of the polysaccharide with 0.1–0.5 molar equivalents of pyridates. In one embodiment, the oxidizing agent is a mixture of a stable nitroxyl radical compound with an oxidizing agent (see WO2014097099). In one respect, the aforementioned stable nitroxyl radical is a molecule containing the TEMPO or PROXYL (5,5,2,2-tetramethyl-1-pyrrolidinyloxy) (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably, this molecule can selectively oxidize the primary alcohol in the presence of an oxidizing agent to form aldehyde groups without affecting the secondary hydroxyl groups. More preferentially, this molecule can selectively oxidize the primary alcohol in the presence of an oxidizing agent to form aldehyde groups without excessive oxidation to carboxyl groups. In one respect, the aforementioned stable nitroxyl radical is TEMPO, 6,6,2,2-tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 2,2,6,6-tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, free 4-(2-Iodoacetamido)-TEMPO radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, or 4-Amino-TEMPO, 4-acetamido-6,6,2,2-tetramethylpiperidine 1-oxyl 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl.Preferably, the aforementioned stable nitroxyl radical is a TEMPO. In one respect, the aforementioned stable nitroxyl radical is selected from the groups consisting of TEMPO, 6,6,2,2-tetramethyl-4-(methylsulfonyloxy)-1-piperidinoxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, free 4-(2-Iodoacetamido)-TEMPO radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-acetamido-6,6,2,2-tetramethylpiperidine-1-oxyl. Preferably, the aforementioned stable nitroxyl radical is TEMPO. Alternatively, the aforementioned stable nitroxyl radical is 3β-DOXYL-5α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-5,5,2,2-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, or 3-Cyano-PROXYL.In addition, the aforementioned stable nitroxyl radical is selected from the groups consisting of 3β-DOXYL-5α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-5,5,2,2-tetramethyl-3-pyrrolene-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. In one respect, the oxidizing agent is a molecule containing an N-halo moiety. Preferably, this molecule has the ability to selectively oxidize the primary alcohol in the presence of a nitroxyl moiety. On one hand, the aforementioned oxidizing agent is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid, or 1,3,5-triiodo-5,3,1-triiodo-2,4,6-trione 1,3,5-triiodo-1,3,5-triiodo-2,4,6-trione.In one respect, the aforementioned oxidizing agent is selected from a group consisting of N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, dichloroisuccianuric acid, 5,3,1-trichloro-5,3,1-triazinan-6,4,2-trione, dibromoisuccianuric acid, 5,3,1-tribromo-5,3,1-triazinan-6,4,2-trione, diiodoisuccianuric acid, and 5,3,1-triiodo-5,3,1-triazinan-6,4,2-trione. N-chlorosuccinimide is preferred as the oxidizing agent. On one hand, the aforementioned stable nitroxyl radical is a free 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) radical, and the aforementioned oxidizing agent is N-Chlorosuccinimide (NCS). In one embodiment, the quenching agent is selected from step (a) of adjacent diols, 1,2-amino alcohols, amino acids, glutathione, sulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites, hypophosphites or phosphorous acid. In one embodiment, the quenching agent is a 1,2-aminoalcohol of formula (I): (I) Where R1 is selected from H, methyl, ethyl, propyl or isopropyl. In one incarnation, the quenching agent is selected from sodium and potassium salts of sulfite, bisulfite, dithionite, metabisulfite, thiosulfate, phosphite, hypophosphite or phosphoric acid. In one incarnation, the quenching agent is an amino acid. In such incarnations, the amino acid in question could be chosen from serine, threonine, cysteine, methionine, proline, hydroxyproline, tryptophan, tyrosine, and histidine. In one of the incarnations, the quenching agent is a sulfite such as bisulfite, dithionite, metabisulfite, thiosulfate. In one embodiment, the quenching agent is a compound containing two adjacent hydroxyl groups (adjacent diols), i.e., two hydroxyl groups covalently bonded to two adjacent carbon atoms. Ideally, the quenching agent should be a compound of the formula (II): (II) R1 and R2 are selected independently from H, methyl, ethyl, propyl or isopropyl. In a preferred emulsion, the quenching agent is glycerol, ethylene glycol, propan-1,2-diol, butan-1,2-diol, butan-2,3-diol, or ascorbic acid. In another preferred emulsion, the quenching agent is butan-2,3-diol. In a preferred embodiment, the degree of oxidation (also called "degree of activation" in the present document) of activated pneumococcal polysaccharide ranges between 2 and 30. In one embodiment, the degree of oxidation (DO) of activated pneumococcal polysaccharide ranges between 10 and 25. In one incarnation, the activated polysaccharide and carrier protein are lyophilized prior to step (b). In one incarnation, the initial input ratio (wtw) of the polysaccharide from activated pneumococci to the carrier protein in step (b) ranges between 1:4 and 1:0.1. In one incarnation, the initial input ratio (wtw) of the polysaccharide from activated pneumococci to the carrier protein in step (b) ranges between 1:1.5 and 1:0.5. In one embodiment, the reduction reaction (C) takes place in an aqueous solvent. In another embodiment, the reduction reaction (C) takes place in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, reduction reaction (C) is carried out in the presence of diethylformamide (DMF). In another embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (C) is carried out in a solution consisting mainly of dimethyl sulfoxide (DMSO) or diethylformamide (DMF). In one embodiment, the reduction reaction (C) is carried out in a solution consisting mainly of diethylformamide (DMF). In another embodiment, the reduction reaction (C) is carried out in a solution consisting mainly of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (C) is carried out in DMSO (dimethyl sulfoxide) or DMF (diethylformamide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranes such as pyridine borane, 2-picoline borane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridine borane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In one preferred incarnation, the reducing agent is sodium cyanoborate hydride. In another incarnation, the reducing agent is sodium cyanoborate hydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 20 molar equivalents of the reducing agent are used in step (c). In another embodiment, between 0.5 and 10 molar equivalents of the reducing agent are used in step (c). In yet another embodiment, between 1.0 and 5 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, unreacted aldehyde groups may remain in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In another embodiment, the covering is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In yet another embodiment, the covering is achieved by mixing the product from step (c) with 1 to 10 molar equivalents of sodium borohydride. In a third embodiment, the covering is achieved by mixing the product from step (c) with 1 to 5 molar equivalents of sodium borohydride. CDI and / or CDT Chemistry In one embodiment, part or all of the glycoconjugates of the pneumococcal species of the present invention are prepared using CDI and / or CDT chemistry as described in WO2022249107. The chemistry of CDI and / or CDT involves two steps: (1) the reaction of the pneumococcal polysaccharide with CDI and / or CDT in a protonated solvent to produce an activated polysaccharide (activation), and (2) the reaction of the activated polysaccharide with a carrier protein (e.g., CRM197, TT, or SCP) to form a glycoconjugate. In one incarnation, the activating factor from step (1) is 1,1ˊ-carbonyldiimidazole (CDI). In another incarnation, the activating factor from step (1) is 1,1ˊ-carbonyl-di-(1,2,4-triazole) (CDT). As mentioned above, prior to activation with CDI and / or CDT, the polysaccharide from pneumococcal can be scaled to a target molecular weight (MW) range. Therefore, in one incarnation, the pneumococcal polysaccharide is sized prior to activation using CDI. In another incarnation, the isolated polysaccharide is sized prior to activation using CDT. In yet another incarnation, the pneumococcal polysaccharide is sized to any target molecular weight (MW) range specified above. Therefore, in one incarnation, the polysaccharide from pneumococci is conjugated to a carrier protein through a process that includes the following steps: (a) The isolated polysaccharide mentioned reacts with CDI and / or CDT in a protonated solvent; (b) The activated polysaccharide from step (a) reacts with a carrier protein in a protonated solvent to form a glycoconjugate. After step (a), it is noted that the polysaccharide is activated and referred to as the "activated polysaccharide". In one incarnation, step (a) involves the reaction of the pneumococcal polysaccharide with CDI. In one embodiment, step (a) involves the reaction of pneumococcal polysaccharide with an amount of CDI ranging from 0.5-10 molar equivalents to an amount of pneumococcal polysaccharide present in the reaction mixture. In one incarnation, step (a) involves the reaction of the pneumococci polysaccharide with CDT. In one embodiment, step (a) involves the reaction of pneumococcal polysaccharide with an amount of CDT ranging from 0.5-10 molar equivalents to an amount of pneumococcal polysaccharide present in the reaction mixture. In one embodiment, activation reaction (A) is carried out in the presence of dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone, or hexamethylphosphoramide (HMPA). In another embodiment, activation reaction (A) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, activation reaction (a) is carried out in a solution consisting mainly of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, the conjugation reaction (b) is carried out in the presence of dimethyl sulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphoramide (HMPA). In one of the incarnations, the activation reaction (b) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the conjugation reaction (b) is carried out in a solution consisting mainly of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). In one embodiment, a weak organic base can be added to the reaction mixture after the activation reaction (A) but before the conjugation reaction (B). The weak organic base can be added either before or after the introduction of the carrier protein into the reaction mixture. Therefore, in one embodiment, the weak organic base is added to the reaction mixture before the introduction of the carrier protein. In another embodiment, the weak organic base is added to the reaction mixture after the introduction of the carrier protein. The weak organic base can be selected from the alkanamines, imidazole, triazole, pyridine, histidine, and guanidine.Alkanamines include primary alkyl amines such as methylamine, ethylamine, propylamine, and isopropylamine; secondary alkyl amines such as dimethylamine, diethylamine, dipropylamine, and diisopropylamine; and tertiary alkyl amines such as trimethylamine, triethylamine, tri-isopropylamine, di-N,Nˊ-isopropylethylamine, and others. In one incarnation, the weak organic base is an alkanamine. In another, it is an imidazole. In yet another, it is a triazole. In another, it is a pyridine. In one incarnation, the weak organic base is histidine. In another incarnation, the weak organic base is guanidine. In one embodiment, following conjugation reaction (b), the non-conjugated reactive sites of the activated polysaccharide are hydrolyzed. In another embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous solution to the conjugation solution. In yet another embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous diluent solution to the conjugation solution. In another embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous diluent solution to the conjugation solution and adjusting the pH between approximately 3.0 and approximately 10.0. In yet another embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous diluent solution to the conjugation solution and adjusting the pH between approximately 7.0 and approximately 10.0. In another embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous diluent solution to the conjugation solution and adjusting the pH between approximately 3.0 and approximately 7.0. In one embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous antibody solution to the conjugation solution and adjusting the pH to approximately 4.0.In one embodiment, the non-conjugated reactive sites are hydrolyzed by adding an aqueous denaturant solution to the conjugation solution and adjusting the pH to approximately 9.0. eTEC Chemistry In one embodiment, part or all of the glycoconjugates of the pneumococci specific to the present invention are prepared using eTEC chemistry as described in WO2014027302. The eTEC spacer contains seven linear atoms (i.e., –C(O)NH(CH2)2SCH2C(O)-) and provides stable amide and thioether bonds between the polysaccharide and the carrier protein. Synthesis of the eTEC-associated glycoconjugate involves the reaction of the polysaccharide's activated hydroxyl group with the amino group of a thioalkylamine reagent, e.g., cysteamine, cysteamine, or a salt thereof, forming a carbamate bond to the polysaccharide to yield a thiol-treated polysaccharide. One or more free sulfhydryl groups are generated by reaction with a reducing agent to provide an activated thiol-treated polysaccharide. The reaction of the activated thiol-treated polysaccharide's free sulfhydryl groups with an activated carrier protein containing one or more α-haloacetamide groups on amine-containing residues leads to the formation of a thioether bond to form the conjugate, whereby the carrier protein is associated with the eTEC spacer via an amine bond. Therefore, in one embodiment, the pneumococcal glycoconjugate of the present invention includes a pneumococcal saccharide covalently conjugated to a carrier protein via a spacer (2-((2-oxoethyl)thio)ethyl)carbamate (2-((2-oxoethyl)thio)ethyl)carbamate(eTEC). In one embodiment, part or all of the pneumococcal glycoconjugates of the present invention include a pneumococcal saccharide conjugated to a carrier protein via a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, where the saccharide is covalently linked to the eTEC spacer via a carbamate connection, and where the carrier protein is covalently linked to the eTEC spacer via an amide connection. The glycosides associated with the invention eTEC can be represented by the general formula (III): (III), where (polysaccharide) represents the polysaccharide of pneumococci. Formula (III) is a schematic representation of the invention's glycoconjugates. It is important to understand that only one linkage between the polysaccharide and the carrier protein is shown. Alternatively, a single carrier protein molecule can bind to more than one polysaccharide molecule from a single pneumococci, and a single polysaccharide molecule can bind to more than one single carrier protein molecule. Furthermore, the majority of the polysaccharide repeat units remain unchanged, and covalent linkages between the carrier protein and the polysaccharide are present in a minority of the polysaccharide repeat units. Tachychemistry In one embodiment, part or all of the glycoconjugates of the pneumococci specific to the present invention are prepared using nitric chemistry (see, for example, PCT / IB2023 / 050202). Therefore, in one embodiment, part or all of the pneumococcal glycoconjugates of the present invention include a pneumococcal saccharide covalently conjugated to a carrier protein (CP) via a spacer and have the general formula (IV): (IV), Where X is selected from the group consisting of CH2(CH2)n', (CH2CH2O)mCH2CH2, NHCO(CH2)n', NHCO(CH2CH2O)mCH2CH2, OCH2(CH2)n' and O(CH2CH2O)mCH2CH2; where n' is selected from 1 to 10 and m is selected from 1 to 4, Where X' is selected from the set consisting of CH2O(CH2)n''CH2C=O, CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4, Where the structure in the square bracket represents a repeating unit of the pneumococcal polysaccharide and where n represents the number of repeating units. In a specific aspect, the invention is directed to a pneumococcal glycoconjugate containing a pneumococcal polysaccharide covalently conjugated to a carrier protein (CP) via a spacer and having the general formula (IV), where X is CH2(CH2)n', where n' is 2 and where X' is CH2O(CH2)n''CH2C=O where n'' is 1. In a specific aspect, the invention relates to a pneumococcal glycoconjugate containing a pneumococcal polysaccharide covalently conjugated to a carrier protein (CP) via a spacer and having the general formula (V). (V) Where the structure in the square bracket represents the polysaccharide repeat unit of the pneumococcal, and where n represents the number of repeat units. In one respect, part or all of the pneumococcal glycoconjugates of the present invention comprise a pneumococcal saccharide covalently conjugated to a carrier protein (CP) via a spacer and have the general formula (VI): (VI), Where X is selected from the set consisting of CH2(CH2)n', (CH2CH2O)mCH2CH2, NHCO(CH2)n', NHCO(CH2CH2O)mCH2CH2, OCH2(CH2)n' and O(CH2CH2O)mCH2CH2; where n' is selected from 0 to 10 and m is selected from 1 to 4, Where X' is selected from the set consisting of CH2(CH2)n”, CH2O(CH2)n''CH2, CH2O(CH2CH2O)m'(CH2)n''CH2, where n'' is selected from 0 to 10 and m' is selected from 0 to 4, where the structure in the square bracket represents a repeating unit of the polysaccharide from pneumococcal and where n represents the number of repeating units. In a specific aspect, the invention is directed to a pneumococcal glycoconjugate containing a pneumococcal polysaccharide covalently conjugated to a carrier protein (CP) via a spacer and having the general formula (VI), where X is CH2(CH2)n', where n' is zero and where X' is CH2(CH2)n', where n' is zero. In a specific aspect, the invention relates to a pneumococcal glycoconjugate containing a pneumococcal polysaccharide covalently conjugated to a carrier protein (CP) via a spacer and having the general formula (VII). (VII) Where the structure in the square bracket represents the polysaccharide repeat unit of the pneumococcal and where n represents the number of repeat units. Formulas (IV), (V), (VII), and (VII) are schematic representations of the invention's glycoconjugates. It should not be understood that there is a covalent bond at every repeating polysaccharide unit (the construct in square brackets). Instead, most of the repeating polysaccharide unit remains unmodified, and covalent bonds exist between the carrier protein and the polysaccharide for a minority of the repeating polysaccharide units. Furthermore, a single carrier protein (CP) molecule can bind to more than one polysaccharide molecule, and a single polysaccharide molecule can bind to more than one carrier protein (CP) molecule. The construct in square brackets represents a repeating polysaccharide unit from Streptococcus pneumoniae. After conjugation with the carrier protein, the glycoconjugates of the invention's pneumococci (enriched for the amount of glycoconjugate and protein) can be purified by a variety of techniques known to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the invention's glycoconjugate includes a purification step after production. 4.1 Glycoconjugates of Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F specific to the invention In one respect, the invention relates to formulations containing the diabetic conjugate(s) of Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F. The polysaccharide constructs of Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F are known in the art of manufacturing (see, for example, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the capsular polysaccharide of Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F used in the present invention is a synthetic carbohydrate. The capsular polysaccharide of Streptococcus pneumoniae serotype 1 can be prepared, for example, as shown in WO2015004041. The capsular polysaccharide of synthetic Streptococcus pneumoniae serotype 4 can be prepared, for example, as shown in WO2016091399. The capsular polysaccharide of Streptococcus pneumoniae serotype 5 can be prepared, for example, as shown in WO2016198170. The capsular polysaccharide can be prepared from the serotype of Streptococcus pneumoniae 8 as shown in WO2017220753. In a preferred embodiment, the source of bacterial polysaccharides under this invention may be Streptococcus pneumoniae bacteria. Bacterial strains that can be used as a source of encapsulated polysaccharides from Streptococcus pneumoniae may be obtained from designated culture collections (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Capsular polysaccharides can be obtained from Streptococcus pneumoniae serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F directly from bacteria using isolation procedures known to a layman in the art of manufacturing. They can also be purchased (for example, from the American Agriculture Printing Group (ATCC, Manassas, VA USA (for example, reference no. ATCC 13-X, ATCC 36-X, ATCC 41-X, ATCC 280-X, ATCC 107-X, ATCC 284-X, ATCC 505-X, ATCC 331-X, ATCC 511-X, ATCC 514-X, ATCC 517-X, ATCC 520-X, ATCC 81-X, ATCC 289-X, ATCC 304-X, ATCC 101-X, ATCC 527-X, ATCC 104-X, ATCC 535-X)). If capsular polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the capsular polysaccharide-producing Streptococcus pneumoniae cells, the bacterial cells can be lysed to produce cell lysate. The capsular polysaccharides can then be isolated from the cell lysate using purification techniques known in the art of chemistry, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified capsular polysaccharides can then be used to prepare glycoconjugates. Isolated capsular polysaccharides can be distinguished by various parameters including, for example, molecular weight (Mw) average weight. The molecular weight of capsular polysaccharides can be measured by volumetric exclusion chromatography (SEC) with a multi-angle laser light scattering detector (MALLS). In one preferred incarnation, the isolated capsular polysaccharides (i.e., purified before further processing) have an average molecular weight between 5 kDa and 5,000 kDa. In another incarnation, the isolated capsular polysaccharides have an average molecular weight between 10 kDa and 3,000 kDa. In yet another incarnation, the isolated capsular polysaccharides have an average molecular weight between 50 kDa and 1,000 kDa. Any integer within any of the ranges mentioned above is expected as an embodiment of the detection. To create conjugates with specific filtration, immunogenicity, and / or yield properties, the capsular polysaccharide can be sized to a target molecular weight range prior to conjugation with a carrier protein. Usefully, the size of the capsular polysaccharide from purified serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical sizing can be employed (see, for example, WO2006 / 110381, WO2015110941). In one of the methods, the volume of the purified capsular polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis can be carried out using a dilute acid (e.g., acetic acid, formic acid, propanoic acid). Alternatively, it can be carried out using a dilute strong acid (e.g., dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid, or dilute perchloric acid). The size of the purified polysaccharide can also be reduced by mechanical homogenization. In one application, the size of the purified polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate increases with a higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed stream through the homogenizer. In one of the incarnations, the capsular polysaccharide of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F isolated is not scaled. O-acetyl can be removed from the isolated serotype 1 capsular polysaccharide (see, for example, WO 2008 / 079653). Therefore, in one incarnation, O-acetyl is partially removed from the isolated serotype 1 capsular polysaccharide. In another incarnation, O-acetyl is removed using a dilute base. O-acetyl can also be partially removed using a sodium carbonate / bicarbonate buffer. In one incarnation, the preconjugated serotype 1 capsular polysaccharide has an average molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated serotype 1 capsular polysaccharide has an average molecular weight between 150 kDa and 900 kDa. In a preferred incarnation, the preconjugated serotype 1 capsular polysaccharide has an average molecular weight between 150 kDa and 700 kDa. The average molecular weight (Mw) of the postconjugated polysaccharide refers to the molecular weight before the polysaccharide is activated (i.e., after a final sizing step but before the polysaccharide reacts with an activating agent). In one incarnation, the preconjugated serotype 4 capsular polysaccharide has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated serotype 4 capsular polysaccharide has a mean molecular weight between 300 kDa and 900 kDa. In one incarnation, the preconjugated serotype 5 capsular polysaccharide has a mean molecular weight between 100 kDa and 1,000 kDa. In another incarnation, the preconjugated serotype 5 capsular polysaccharide has a mean molecular weight between 200 kDa and 600 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 6A has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 6A has a mean molecular weight between 300 kDa and 900 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 6B has a mean molecular weight between 100 kDa and 1000 kDa. In yet another incarnation, the preconjugated capsular polysaccharide isolated from serotype 6B has a mean molecular weight between 200 kDa and 900 kDa. In one incarnation, the preconjugated serotype 7F capsular polysaccharide has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated serotype 7F capsular polysaccharide has a mean molecular weight between 200 kDa and 900 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 8 has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 8 has a mean molecular weight between 200 kDa and 400 kDa. In one incarnation, the preconjugated serotype 9V capsular polysaccharide has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated serotype 9V capsular polysaccharide has a mean molecular weight between 200 kDa and 900 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 10A has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 10A has a mean molecular weight between 200 kDa and 900 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 11A has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 11A has a mean molecular weight between 100 kDa and 400 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 12F has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 12F has a mean molecular weight between 150 kDa and 400 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 14 has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 14 has a mean molecular weight between 200 kDa and 900 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 15B has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 15B has a mean molecular weight between 150 kDa and 300 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 18C has a mean molecular weight between 20 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 18C has a mean molecular weight between 20 kDa and 500 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 19A has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 19A has a mean molecular weight between 250 kDa and 700 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 19F has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 19F has a mean molecular weight between 250 kDa and 800 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 22F has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 22F has a mean molecular weight between 400 kDa and 700 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 23F has a mean molecular weight between 100 kDa and 1000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 23F has a mean molecular weight between 200 kDa and 800 kDa. In one incarnation, the preconjugated capsular polysaccharide isolated from serotype 33F has a mean molecular weight between 300 kDa and 2000 kDa. In another incarnation, the preconjugated capsular polysaccharide isolated from serotype 33F has a mean molecular weight between 500 kDa and 2000 kDa. In one embodiment, the serotype 1 glycosurfactant of the present invention contains a serotype 1 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 750 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 250 kDa to 600 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 4 glycosurfactant of the present invention contains a serotype 4 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 1,000 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 400 kDa to 900 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 5 glycosurfactant of the present invention contains a serotype 5 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 100 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 150 kDa to 800 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 200 kDa to 500 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 6A glycoconjugate of the present invention comprises a serotype 6A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 1,000 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 800 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 6B glycoconjugate of the present invention comprises a serotype 6B encapsulated polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 1,000 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 800 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 7F glycoconjugate of the present invention comprises a serotype 7F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 1,000 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 800 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 8 glycoconjugate of the present invention comprises a serotype 8 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 800 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 600 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 200 kDa to 400 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 9V glycoconjugate of the present invention comprises a serotype 9V capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 900 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 600 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 100 kDa to 400 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 10A glycoconjugate of the present invention comprises a serotype 10A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 200 kDa to 800 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 300 kDa to 600 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 100 kDa to 400 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 11A glycoconjugate of the present invention comprises a serotype 11A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 75 kDa to 600 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 100 kDa to 400 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 12F glycoconjugate of the present invention comprises a serotype 12F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 100 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 150 kDa to 600 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 150 kDa to 400 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 250 kDa to 350 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 14 glycoconjugate of the present invention comprises a serotype 14 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 800 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 200 kDa to 600 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 15B glycoconjugate of the present invention comprises a serotype 15B encapsulated polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 600 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 150 kDa to 300 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 18C glycoconjugate of the present invention comprises a serotype 18C encapsulated polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 20 kDa to 800 kDa. In another embodiment, the average molecular weight (Mw) ranges from 20 kDa to 400 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 20 kDa to 200 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 19A glycoconjugate of the present invention comprises a serotype 19A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 700 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 250 kDa to 500 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 19F glycosurfactant of the present invention contains a serotype 19F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 900 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 250 kDa to 600 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 22F glycoconjugate of the present invention comprises a serotype 22F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 900 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 400 kDa to 700 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 23F glycoconjugate of the present invention comprises a serotype 23F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 900 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 200 kDa to 600 kDa. The average molecular weight (Mw) prior to conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In one embodiment, the serotype 33F glycoconjugate of the present invention comprises a serotype 33F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide before conjugation ranging from 50 kDa to 2,500 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 2,000 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 600 kDa to 2,000 kDa. The average molecular weight (Mw) before conjugation refers to the molecular weight after activation of the polysaccharide (i.e., after a final sizing step and after the polysaccharide reacts with an activating factor). In some incarnations, the invention's serotype 1 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 1 diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 1 diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some incarnations, the invention's serotype 4 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 4 diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 4 diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some incarnations, the invention's serotype 5 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 5 diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 5 diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some incarnations, the invention's serotype 6A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 6A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 6A diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,000 kDa. In some incarnations, the invention's serotype 6B diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 6B diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 6B diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some incarnations, the serotype 7F diabetic conjugate of the invention has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 7F diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 7F diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some incarnations, the invention's serotype 8 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 8 diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 8 diabetic conjugate has a mean molecular weight (Mw) between 2,500 kDa and 8,000 kDa. In some incarnations, the serotype 9V diabetic conjugate of the invention has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 9V diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 9V diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some incarnations, the invention's serotype 10A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 10A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 10A diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some incarnations, the invention's serotype 11A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 11A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 11A diabetic conjugate has a mean molecular weight (Mw) between 700 kDa and 4,500 kDa. In some incarnations, the invention's serotype 12F diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 12F diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 12F diabetic conjugate has a mean molecular weight (Mw) between 1,500 kDa and 4,000 kDa. In some incarnations, the invention's serotype 14 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 14 diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 14 diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,500 kDa. In some incarnations, the invention's serotype 15B diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 25,000 kDa. In other incarnations, the serotype 15B diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 20,000 kDa. In preferred incarnations, the serotype 15B diabetic conjugate has a mean molecular weight (Mw) between 5,000 kDa and 15,000 kDa. In some incarnations, the serotype 18C diabetic conjugate of the invention has a mean molecular weight (Mw) between 150 kDa and 15,000 kDa. In other incarnations, the serotype 18C diabetic conjugate has a mean molecular weight (Mw) between 250 kDa and 7,000 kDa. In preferred incarnations, the serotype 18C diabetic conjugate has a mean molecular weight (Mw) between 300 kDa and 4,000 kDa. In some incarnations, the invention's serotype 19A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 19A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. In preferred incarnations, the serotype 19A diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 7,500 kDa. In some incarnations, the invention's serotype 19F diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 19F diabetic conjugate has a mean molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred incarnations, the serotype 19F diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In some incarnations, the invention's serotype 22F diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 10,000 kDa. In other incarnations, the serotype 22F diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In preferred incarnations, the serotype 22F diabetic conjugate has a mean molecular weight (Mw) between 2,500 kDa and 5,500 kDa. In some incarnations, the invention's serotype 23F diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 23F diabetic conjugate has a mean molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred incarnations, the serotype 23F diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 7,500 kDa. In some incarnations, the invention's serotype 33F diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In other incarnations, the serotype 33F diabetic conjugate has a mean molecular weight (Mw) between 750 kDa and 10,000 kDa. In preferred incarnations, the serotype 33F diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 6,000 kDa. The invention-specific glycosides can also be distinguished by the ratio (w / w) of saccharide to carrier protein. In some incarnations, the ratio of serotype 1 polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.6 and 2.0. In some of these incarnations, the carrier protein is TT. Ideally, it is CRM197. In some incarnations, the ratio of serotype 4 polysaccharides to the carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.9 and 2.1. Even more ideally, it is between 1.0 and 1.9. In some of these incarnations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 5 polysaccharides to the carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 1.3 and 2.5. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 6A polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.7 and 1.6. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 6B polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.4 and 0.8. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 7F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.7 and 1.5. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 8 polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.6 and 1.6. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 9V polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 1.2 and 2.3. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 10A polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.7 and 1.6. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 11A polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.9 and 1.5. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 12F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.7 and 1.5. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 14 polysaccharides to the carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 1.4 and 2.6. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 15B polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.6 and 1.6. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 18C polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.7 and 1.5. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 19A polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.4 and 0.9. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 19F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.5 and 1.0. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 22F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.8 and 1.2. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 23F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 0.4 and 1.0. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. In some translocations, the ratio of serotype 33F polysaccharide to carrier protein in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the ratio is between 1.0 and 2.2. In some of these translocations, the carrier protein is TT. Ideally, it is CRM197. Another method for characterizing the invention's glycoconjugates is by the number of lysine residues present in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a set of conjugated lysines (degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods familiar to those skilled in the art of synthesis. Conjugation results in a reduced number of recovered lysine residues compared to the carrier protein starter material used to create the conjugate material. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of serotype 1 of the invention ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of serotype 4 of the invention ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of serotype 5 of the invention ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 6A ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 6B ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 7F ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 8 ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 9V ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 10A ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 11A ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 12F ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 14 ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 15B ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 18C ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 19A ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 19F ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 22F ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 23F ranges between 2 and 15. In a preferred embodiment, the degree of conjugation of the diabetic conjugate of the invention's serotype 33F ranges between 2 and 15. The glycosurfactants of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, or 33F of the invention and the immunomodulatory formulations containing the aforementioned glycosurfactant(s) may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present in the glycosurfactant structure. The free polysaccharide may be non-covalently bound to the glycosurfactant (i.e., attached to it, adsorbed to it, or drawn into or with it). In one embodiment, the serotype 1 glycosurfactant of the invention contains less than approximately 40% of the free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In a preferred embodiment, the serotype 1 glycosurfactant contains less than approximately 20% of the free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In one embodiment, the serotype 1 glycosurfactant of the invention contains less than approximately 40% of the free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In a preferred embodiment, the serotype 1 glycosurfactant contains less than approximately 20% of the free serotype 1 polysaccharide compared to the total amount of serotype 1 polysaccharide. In one embodiment, the serotype 4 glycosuric conjugate of the invention includes less than approximately 40% of the free serotype 4 polysaccharide compared to the total amount of serotype 4 polysaccharide. In a preferred embodiment, the serotype 4 glycosuric conjugate includes less than approximately 30% of the free serotype 4 polysaccharide compared to the total amount of serotype 4 polysaccharide. In one embodiment, the serotype 5 glycosurfactant of the invention contains less than approximately 45% of the free serotype 5 polysaccharide compared to the total amount of serotype 5 polysaccharide. In a preferred embodiment, the serotype 5 glycosurfactant contains less than approximately 40% of the free serotype 5 polysaccharide compared to the total amount of serotype 5 polysaccharide. In one embodiment, the serotype 6A glycosurfactant of the invention contains approximately 40% less free serotype 6A polysaccharides compared to the total amount of serotype 6A polysaccharides. In a preferred embodiment, the serotype 6A glycosurfactant contains approximately 30% less free serotype 6A polysaccharides compared to the total amount of serotype 6A polysaccharides. In one embodiment, the serotype 6B glycosurfactant of the invention contains approximately 30% less free serotype 6B polysaccharides compared to the total amount of serotype 6B polysaccharides. In a preferred embodiment, the serotype 6B glycosurfactant contains approximately 20% less free serotype 6B polysaccharides compared to the total amount of serotype 6B polysaccharides. In one embodiment, the serotype 7F glycosurfactant of the invention contains approximately 30% less free serotype 7F polysaccharides compared to the total amount of serotype 7F polysaccharides. In a preferred embodiment, the serotype 7F glycosurfactant contains approximately 20% less free serotype 7F polysaccharides compared to the total amount of serotype 7F polysaccharides. In one incarnation, the serotype 8 diabetic conjugate includes less than about 30% of the free serotype 8 polysaccharide compared to the total amount of serotype 8 polysaccharide. In a preferred incarnation, the serotype 8 diabetic conjugate includes less than about 20% of the free serotype 8 polysaccharide compared to the total amount of serotype 8 polysaccharide. In one embodiment, the serotype 9V glycosurfactant of the invention contains approximately 40% less free serotype 9V polysaccharides compared to the total amount of serotype 9V polysaccharides. In a preferred embodiment, the serotype 9V glycosurfactant contains approximately 35% less free serotype 9V polysaccharides compared to the total amount of serotype 9V polysaccharides. In one embodiment, the serotype 10A glycosurfactant of the invention contains approximately 40% less free serotype 10A polysaccharides compared to the total amount of serotype 10A polysaccharides. In a preferred embodiment, the serotype 10A glycosurfactant contains approximately 20% less free serotype 10A polysaccharides compared to the total amount of serotype 10A polysaccharides. In one embodiment, the serotype 11A glycosurfactant of the invention contains approximately 40% less free serotype 11A polysaccharides compared to the total amount of serotype 11A polysaccharides. In a preferred embodiment, the serotype 11A glycosurfactant contains approximately 30% less free serotype 11A polysaccharides compared to the total amount of serotype 11A polysaccharides. In one embodiment, the serotype 12F glycosurfactant of the invention contains approximately 40% less free serotype 12F polysaccharides compared to the total amount of serotype 12F polysaccharides. In a preferred embodiment, the serotype 12F glycosurfactant contains approximately 30% less free serotype 12F polysaccharides compared to the total amount of serotype 12F polysaccharides. In one embodiment, the serotype 14 glycosurfactant of the invention contains less than approximately 40% of the free serotype 14 polysaccharide compared to the total amount of serotype 14 polysaccharide. In a preferred embodiment, the serotype 14 glycosurfactant contains less than approximately 35% of the free serotype 14 polysaccharide compared to the total amount of serotype 14 polysaccharide. In one embodiment, the serotype 15B glycosurfactant of the invention contains approximately 40% less free serotype 15B polysaccharides compared to the total amount of serotype 15B polysaccharides. In a preferred embodiment, the serotype 15B glycosurfactant contains approximately 35% less free serotype 15B polysaccharides compared to the total amount of serotype 15B polysaccharides. In one embodiment, the serotype 18C glycosurfactant of the invention contains approximately 30% less free serotype 18C polysaccharides compared to the total amount of serotype 18C polysaccharides. In a preferred embodiment, the serotype 18C glycosurfactant contains approximately 20% less free serotype 18C polysaccharides compared to the total amount of serotype 18C polysaccharides. In one embodiment, the serotype 19A glycosurfactant of the invention contains approximately 40% less free serotype 19A polysaccharides compared to the total amount of serotype 19A polysaccharides. In a preferred embodiment, the serotype 19A glycosurfactant contains approximately 30% less free serotype 19A polysaccharides compared to the total amount of serotype 19A polysaccharides. In one incarnation, the serotype 19F glycosurfactant of the invention contains approximately 30% less free serotype 19F polysaccharides compared to the total amount of serotype 19F polysaccharides. In a preferred incarnation, the serotype 19F glycosurfactant contains approximately 20% less free serotype 19F polysaccharides compared to the total amount of serotype 19F polysaccharides. In one embodiment, the serotype 22F glycosurfactant of the invention contains approximately 40% less free serotype 22F polysaccharides compared to the total amount of serotype 22F polysaccharides. In a preferred embodiment, the serotype 22F glycosurfactant contains approximately 20% less free serotype 22F polysaccharides compared to the total amount of serotype 22F polysaccharides. In one embodiment, the serotype 23F glycosurfactant of the invention contains approximately 30% less free serotype 23F polysaccharides compared to the total amount of serotype 23F polysaccharides. In a preferred embodiment, the serotype 23F glycosurfactant contains approximately 20% less free serotype 23F polysaccharides compared to the total amount of serotype 23F polysaccharides. In one embodiment, the serotype 33F glycosurfactant of the invention contains approximately 30% less free serotype 33F polysaccharides compared to the total amount of serotype 33F polysaccharides. In a preferred embodiment, the serotype 33F glycosurfactant contains approximately 20% less free serotype 33F polysaccharides compared to the total amount of serotype 33F polysaccharides. The glycolytic conjugate of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, or 33F of the invention can also be distinguished by its molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of the conjugates. Larger molecules excluded from the pores in the media are rinsed off more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the bars are calibrated to create a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression, Kd = (Ve - V0) / (Vi - V0). In one incarnation, at least 40% of diabetic conjugates of serotype 1Kd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 50% and 80% of diabetic conjugates of serotype 1Kd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 4Kd have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, at least 40% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, between 40% and 80% of diabetic conjugates of serotype 4Kd have a CL-4B affinity less than or equal to 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 5Kd have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, at least 55% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, between 55% and 80% of diabetic conjugates of serotype 5Kd have a CL-4B affinity less than or equal to 0.3. In one incarnation, at least 50% of diabetic conjugates of serotype 6AKd have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, at least 60% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, between 60% and 90% of diabetic conjugates of serotype 6AKd have a CL-4B affinity less than or equal to 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 6BKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 35% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 35% and 80% of diabetic conjugates of serotype 6BKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 50% of diabetic conjugates of serotype 7FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 65% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 65% and 90% of diabetic conjugates of serotype 7FKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 60% of diabetic conjugates of serotype 8Kd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 70% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 70% and 90% of diabetic conjugates of serotype 8Kd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 9VKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 40% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 40% and 80% of diabetic conjugates of serotype 9VKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 10AKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 55% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 55% and 85% of diabetic conjugates of serotype 10AKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 50% of diabetic conjugates of serotype 11AKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 60% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 60% and 85% of diabetic conjugates of serotype 11AKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 12FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 50% and 80% of diabetic conjugates of serotype 12FKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 14Kd have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred incarnation, between 50% and 80% of diabetic conjugates of serotype 14Kd have a CL-4B affinity less than or equal to 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 15BKd have a CL-4B chromosome less than or equal to 0.3. In a preferred incarnation, at least 40% of diabetic conjugates have a CL-4B chromosome less than or equal to 0.3. In a preferred incarnation, between 40% and 80% of diabetic conjugates of serotype 15BKd have a CL-4B chromosome less than or equal to 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 18CKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 40% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 40% and 80% of diabetic conjugates of serotype 18CKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 19AKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 50% and 80% of diabetic conjugates of serotype 19AKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 40% of diabetic conjugates of serotype 19FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 50% and 80% of diabetic conjugates of serotype 19FKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 22FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 40% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 40% and 80% of diabetic conjugates of serotype 22FKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 30% of diabetic conjugates of serotype 23FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 35% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 35% and 80% of diabetic conjugates of serotype 23FKd have a CL-4B affinity ≤ 0.3. In one incarnation, at least 50% of diabetic conjugates of serotype 33FKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 60% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 60% and 95% of diabetic conjugates of serotype 33FKd have a CL-4B affinity ≤ 0.3. In one incarnation, a polysaccharide of serotype 1,4,5,6A,6B,7F,8,9V,10A,11A,12F,14,15B,18C,19A,19F,22F,23F, and / or 33F is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein. For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In one of the incarnations, glycoconjugates of the invention-specific serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F are prepared using amine reduction chemistry. According to the present invention, the reducing amine group involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate (see, for example, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, glycoconjugates of the invention-specific serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F are prepared using amine reducing chemistry. In another embodiment, glycoconjugates of the invention-specific serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, and 23F are prepared using amine reducing chemistry. As mentioned above, prior to oxidation, the isolated serotype capsular polysaccharides 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F can be sized to a target molecular weight (MW) range. Therefore, in one embodiment, the isolated serotype capsular polysaccharides 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F are sized prior to oxidation. Therefore, in one of the incarnations, the encapsulated polysaccharide of the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F isolated prior to oxidation is scalable. In one embodiment, the isolated capsular polysaccharide of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F is conjugated to a carrier protein through a process that includes the following steps: (a) Reaction of the encapsulated polysaccharide of serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F isolated mentioned with an oxidizing agent to produce an activated polysaccharide; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) Reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. After step (a) of oxidation, it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one incarnation, capsular polysaccharides of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F isolated react with pyridates. In one incarnation, capsular polysaccharides of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, and 23F isolated react with pyridates. In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In an even more preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide-pyridate reaction" includes the oxidation of adjacent hydroxyl groups using pyridates. In one embodiment, step (a) involves the reaction of serotype polysaccharides 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with pyridates. In one embodiment, step (a) involves the reaction of serotype polysaccharides 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with 0.05-2 molar equivalents of pyridates. In one embodiment, step (a) involves the reaction of serotype polysaccharides 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with 0.05-2 molar equivalents of pyridates. In one embodiment, step (a) involves the reaction of a serotype polysaccharide 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with 0.2-0.5 molar equivalents of pyridates. In one embodiment, step (a) involves the reaction of a serotype polysaccharide 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with 0.5-1.5 molar equivalents of pyridates. In one embodiment, step (a) involves the reaction of a serotype polysaccharide 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F with 1.5-2.0 molar equivalents of pyridates. In some incarnations, the reaction in step (a) is quenched. Therefore, after step (a), a quenching step (aˊ) can be performed (see WO2015110940). Thus, in one incarnation, the isolated capsular polysaccharide of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F is conjugated to a carrier protein via a process involving the step: (a) Reaction of the encapsulated polysaccharide of serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F isolated mentioned with an oxidizing agent to produce an activated polysaccharide; (aˊ) Quenching of the oxidation reaction by adding a quenching agent resulting from the activated polysaccharide; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) Reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. In one embodiment, the oxidizing agent is a free 6,6,2,2-tetramethyl-1-pyridinyloxy (TEMPO) moiety and N-chlorosuccinimide (NCS) as a co-oxidant. This oxidizing agent is particularly suitable for the oxidation of serotype 12F capsular polysaccharides. In such an embodiment, serotype 12F polysaccharides of Streptococcus pneumoniae are prepared using a free 6,6,2,2-tetramethyl-1-pyridinyloxy (TEMPO) moiety to oxidize the polysaccharide's primary alcohols to aldehydes using N-chlorosuccinimide (NCS) as a co-oxidant (hereafter "TEMPO / NCS oxidation"), e.g., as described in Example 7 and in WO 2014 / 097099.Therefore, in one respect, serotype 12F glycoconjugates of Streptococcus pneumoniae can be readily obtained using a method involving the following steps: (a) reaction of an isolated serotype 12F capsular polysaccharide with 6,6,2,2-tetramethyl-1-pyridinyloxy (TEMPO) and N-chlorosuccinimide (NCS) to produce an activated polysaccharide; (b) synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate (hereafter referred to as the "TEMPO / NCS reducing amine group"). In one respect, serotype 12F glycoconjugates of Streptococcus pneumoniae can be obtained using this method. In one incarnation, the isolated capsular polysaccharides of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F react with pyridates and the isolated capsular polysaccharide of serotype 12F reacts with TEMPO / NCS. In one incarnation, the isolated capsular polysaccharides of serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 18C, 19A, 19F, 22F, and 23F react with pyridates, and the isolated capsular polysaccharide of serotype 12F reacts with TEMPO / NCS. In a preferred embodiment, the degree of oxidation (also called the "activation degree" in the present document) of the activated serotype polysaccharide 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F ranges between 2 and 30. In one incarnation, the oxidation degree of the activated serotype 1 polysaccharide ranges between 1 and 15 when the carrier protein is a TT (see, for example, Table 2 of WO2019 / 152921). In a preferred embodiment, the degree of oxidation of the activated serotype 1 polysaccharide ranges between 4 and 10 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the serotype 4 activated polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the serotype 4 activated polysaccharide ranges from 1 to 5 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the serotype 5 activated polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the serotype 5 activated polysaccharide ranges from 2 to 6 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 5 polysaccharide ranges from 1 to 15 when the carrier protein is TT. See Table 2 of WO2019 / 152921. In one incarnation, the oxidation state of the serotype 6A polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 6A polysaccharide ranges from 5 to 15 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 6B polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 6B polysaccharide ranges from 7 to 13 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 7F polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 7F polysaccharide ranges from 2 to 8 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 8 polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 8 polysaccharide ranges from 1 to 17 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 9V polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 9V polysaccharide ranges from 4 to 9 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 10A polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 10A polysaccharide ranges from 1 to 12 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 11A polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 11A polysaccharide ranges from 1 to 15 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 12F polysaccharide ranges from 1 to 15. In a preferred incarnation, the oxidation state of the activated serotype 12F polysaccharide ranges from 1 to 9 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 14 polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 14 polysaccharide ranges from 6 to 13 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 15B polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 15B polysaccharide ranges from 6 to 17 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 15B polysaccharide ranges from 1 to 15 when the carrier protein is TT. See Table 2 of WO2019 / 152925. In one incarnation, the oxidation state of the activated serotype 18C polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 18C polysaccharide ranges from 6 to 14 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 19A polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 19A polysaccharide ranges from 7 to 13 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 19F polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 19F polysaccharide ranges from 6 to 12 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 22F polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 22F polysaccharide ranges from 1 to 16 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 22F polysaccharide ranges from 1 to 20 when the carrier protein is TT. See Table 2 of WO2019 / 152925. In one incarnation, the oxidation state of the activated serotype 23F polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 23F polysaccharide ranges from 6 to 14 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. In one incarnation, the oxidation state of the activated serotype 33F polysaccharide ranges from 1 to 20. In a preferred incarnation, the oxidation state of the activated serotype 33F polysaccharide ranges from 1 to 15 when the carrier protein is CRM197. See Table 1 of WO2019 / 152921. The activated polysaccharide and the carrier protein can be freeze-dried either independently (separate freeze-drying) or together (co-freeze-drying). In one embodiment, the activated polysaccharide and the carrier protein are co-freezed. In another embodiment, the activated polysaccharide and the carrier protein are freeze-dried independently. In one embodiment, lyophilization takes place in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melezitose, dextran, mannitol, lactitol, and palatinit. In one incarnation, the initial insertion ratio (wt) of the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide to the carrier protein in step (b) ranges between 1:4 and 1:0.1. In one incarnation, the initial insertion ratio (wt) of the serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and / or 33F capsular polysaccharide to the carrier protein ranges between 1:1.5 and 1:0.5. In one embodiment, reduction reaction (C) is carried out in a laprotonized solvent. In another embodiment, reduction reaction (C) is carried out in a solution consisting mainly of dimethyl sulfoxide (DMSO). In yet another embodiment, reduction reaction (C) is carried out in a DMSO (dimethyl sulfoxide) solvent. In one of the reductions, the reduction reaction (C) is carried out in an aqueous solvent. In one of the incarnations, reduction reaction (C) is carried out in DMSO (dimethyl sulfoxide) solvent for serotypes 6A, 6B, 7F, 8, 10A, 15B, 19A, 19F, 22F and 23F, and reduction reaction (C) is carried out in an aqueous solvent for serotypes 1, 4, 5, 9V, 11A, 12F, 14 and 18C. In one of the incarnations, reduction reaction (C) is carried out in DMSO (dimethyl sulfoxide) solvent for serotypes 6A, 6B, 7F, 8, 10A, 15B, 19A, 19F, 22F and 23F, and reduction reaction (C) is carried out in an aqueous solvent for serotypes 1, 4, 5, 9V, 11A, 12F, 14, 18C and 33F. In one of the incarnations, reduction reaction (C) is carried out in DMSO (dimethyl sulfoxide) solvent for serotypes 6A, 6B, 7F, 18C, 19A, 19F and 23F, and reduction reaction (C) is carried out in an aqueous solvent for serotypes 1, 4, 5, 9V, 14, 22F and 33F. In one of the incarnations, reduction reaction (C) is carried out in DMSO (dimethyl sulfoxide) solvent for serotypes 6A, 6B, 7F, 11A, 12F, 19A, 19F and 23F, and reduction reaction (C) is carried out in an aqueous solvent for serotypes 1, 4, 5, 8, 9V, 10A, 14, 15B, 18C, 22F and 33F. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amineborates such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamineborane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 10 molar equivalents of the reducing agent are used in step (c). Preferably, between 0.5 and 5 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, unreacted aldehyde groups may remain in the conjugates, and these can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation to the carrier protein, serotype 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and / or 33F glycoconjugates (enriched relative to the amount of glycoconjugate and protein) can be purified using a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production of the serotype 1 glycoconjugate for the present invention includes a post-production purification step. In some incarnations, the serotype 33F glycosides of the invention are prepared using the reducing amine group. In other incarnations, the invention's serotype 33F glycosides are prepared using eTEC conjugation (hereafter "serotype 33F eTEC-associated glycosides"), such as those described in WO 2014 / 027302 or WO 2015110941 (see Examples 1, 2, and 3). The 33F glycosides described involve a polysaccharide covalently conjugated to a carrier protein via one or more eTEC spacers, where the polysaccharide is covalently conjugated to the eTEC spacer via a carbamate linkage, and where the carrier protein is covalently conjugated to the eTEC spacer via an amide linkage. The invention's eTEC-associated glycosides can be represented by the general formula (III): (III) The atoms containing the eTEC spacers are located in the central box. The eTEC spacer contains seven linear atoms (i.e., –C(O)NH(CH2)2SCH2C(O)-) and provides stable thioether and amide bonds between the polysaccharide and the carrier protein. Synthesis of the eTEC-associated glycoconjugate involves the reaction of an activated hydroxyl group of the polysaccharide with the amino group of a thioalkylamine reagent, e.g., cysteamine, cysteamine, or a salt thereof, forming a carbamate bond with the polysaccharide to yield a thiol-treated polysaccharide. One or more sulfhydryl groups are generated by reacting them with a reducing agent to yield an activated thiol-treated polysaccharide. The reaction of the free sulfhydryl groups of the activated thiol-treated polysaccharide with an activated carrier protein that has one or more α-haloacetamide groups on its amine-containing residues leads to the formation of a thioether bond to form the conjugate, to which the carrier protein is attached to the eTEC spacer via an amide bond. In the invention's serotype 33F eTEC-associated glycosides, the polysaccharide can be either a polysaccharide or an oligosaccharide. The carrier protein can be chosen from any suitable carrier, as described here or known to those skilled in the art of synthesis. Preferably, the polysaccharide is a polysaccharide. In some incarnations, the carrier protein is CRM197. In some of these incarnations, the eTEC-associated glycosidic conjugate includes a capsular polysaccharide of serotype 33F Streptococcus pneumoniae. In particularly favored incarnations, the eTEC-associated glycosurfactant includes the Pn-33F capsular polysaccharide, which covalently conjugates to CRM197 via the eTEC spacer (eTEC-associated glycosurfactants of serotype 33F). In one of the incarnations, the glycoconjugates of the invention's serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F and 23F are prepared using amine reduction chemistry, and the glycoconjugate of the invention's serotype 33F is prepared using eTEC coupling. 5.1 The invention-specific diabetic conjugate of serotype 15A of Streptococcus pneumoniae In one aspect, the invention relates to serotype 15A glycoconjugates of Streptococcus pneumoniae. The construction of the Streptococcus pneumoniae serotype 15A polysaccharide is well known in the art of the industry (see, for example, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the serotype 15A capsular polysaccharide of Streptococcus pneumoniae used in the present invention is a synthetic carbohydrate. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be Streptococcus pneumoniae serotype 15A bacteria. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 15A polysaccharide may be obtained from selected culture kits (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Polysaccharides of serotype 15A can be obtained directly from the bacteria using isolation procedures familiar to any ordinary industrialist. They can also be purchased (e.g., from the American Agriculture Printing Group (ATCC, Manassas, VA USA) (e.g., reference no. ATCC (537-X)). When serotype 15A polysaccharide is obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 15A capsular polysaccharide, the bacterial cells can be lysed to produce cell lysate. The serotype 15A polysaccharide can then be isolated from the cell lysate using purification techniques known in the field of chemistry, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 15A polysaccharide can then be used to prepare glycoconjugates. The isolated serotype 15A capsular polysaccharide can be distinguished by purifying the serotype 15A polysaccharide from Streptococcus pneumoniae lysate and optionally sizing the purified polysaccharide by various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In a preferred incarnation, the isolated serotype 15A capsular polysaccharide (i.e., purified before further processing) has a mean molecular weight between 100 kDa and 2500 kDa. In one incarnation, the isolated serotype 15A capsular polysaccharide has a mean molecular weight between 250 kDa and 1500 kDa. In another incarnation, the isolated serotype 15A capsular polysaccharide has a mean molecular weight between 500 kDa and 1000 kDa. Any whole number within any of the ranges mentioned above is expected as an embodiment of the detection. To create serotype 15A conjugates with characteristic filtration, immunogenicity, and / or yield properties, the polysaccharide can be scaled to a target molecular weight range prior to conjugation with a carrier protein. Beneficially, the size of the purified serotype 15A polysaccharide is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical scaling can be employed. In one of the incarnations, the purified serotype 15A polysaccharide is reduced in volume by chemical hydrolysis. Chemical hydrolysis can be performed using a dilute acid (e.g., acetic acid, formic acid, propanoic acid). Alternatively, chemical hydrolysis can be performed using a dilute strong acid (e.g., dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid, or dilute perchloric acid). Ideally, the size of purified serotype 15A polysaccharides is reduced by mechanical homogenization. In one embodiment, the size of purified serotype 15A polysaccharides is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process current through a sufficiently small flow path. The shear rate increases with a higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed current through the homogenizer. In one incarnation, the isolated serotype 15A capsular polysaccharide is scaled to an intermediate molecular weight between 50 kDa and 500 kDa. In a preferred incarnation, the isolated serotype 15A capsular polysaccharide is scaled to an intermediate molecular weight between 75 kDa and 250 kDa. Preferably, the isolated serotype 15A capsular polysaccharide is scaled to an intermediate molecular weight below 175 kDa. In another preferred incarnation, the isolated serotype 15A capsular polysaccharide is scaled to an intermediate molecular weight between 75 kDa and 175 kDa. In a preferred configuration, the isolated serotype 15A capsular polysaccharide is sized to an intermediate molecular weight between 100 kDa and 175 kDa. Ideally, the isolated serotype 15A capsular polysaccharide is sized by mechanical homogenization, preferably by high-pressure homogenization. In one incarnation, the isolated serous type 15A capsular polysaccharide is not scaled. In one incarnation, the preconjugated serotype 15A capsular polysaccharide has a mean molecular weight between 50 kDa and 500 kDa. In another incarnation, the preconjugated serotype 15A capsular polysaccharide has a mean molecular weight between 75 kDa and 250 kDa. In a preferred incarnation, the preconjugated serotype 15A capsular polysaccharide has a mean molecular weight between 75 kDa and 175 kDa. In yet another preferred incarnation, the preconjugated serotype 15A capsular polysaccharide has a mean molecular weight between 90 kDa and 150 kDa. In a more preferred embodiment, the preconjugated serotype 15A capsular polysaccharide has an intermediate molecular weight between 100 kDa and 175 kDa. The molecular weight (Mw) of the polysaccharide before conjugation refers to the molecular weight before the activation of the polysaccharide (i.e., after a final sizing step but before the polysaccharide reacts with an activating agent). In the context of the present invention, the molecular weight of polysaccharide 15A is not significantly altered by the activation step, and the molecular weight of polysaccharide 15A incorporated into the conjugate is similar to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the serotype 15A glycosurfactant of the present invention contains a serotype 15A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 500 kDa. In another embodiment, the average molecular weight (Mw) ranges from 75 kDa to 350 kDa. In a preferred embodiment, the average molecular weight (Mw) ranges from 75 kDa to 175 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 90 kDa to 150 kDa. In some incarnations, the invention's serotype 15A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 10,000 kDa. In other incarnations, the serotype 15A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 10,000 kDa. Ideally, the serotype 15A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 6,000 kDa. The serotype 15A glycoconjugates of the invention can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 15A polysaccharide-to-carrier protein ratio in the glycoconjugate (w / w) ranges from 0.5 to 3.0. Ideally, the saccharide-to-carrier protein ratio ranges from 0.5 to 1.5. Even more ideally, the saccharide-to-carrier protein ratio (w / w) ranges from 0.7 to 1.1. Another method for distinguishing the patent serotype 15A glycoconjugates is by the number of lysine residues present in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a range of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods known to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the carrier protein starter material used to create the conjugate material. In a preferred embodiment, the degree of conjugation of the patent serotype 15A glycoconjugate ranges from 2 to 20. In a more favorable embodiment, the degree of conjugation of the patent serotype 15A glycoconjugate ranges from 5 to 10. Serotype 15A glycoconjugates and invention-specific immunomodulatory formulations may contain a free saccharide that is not covalently conjugated to the carrier protein but is instead present in the glycoconjugate structure. The free saccharide may be non-covalently bound to the glycoconjugate (i.e., attached to it, adsorbed to it, or drawn into or with it). In one incarnation, the serotype 15A glycosurfactant contains approximately 40% less free serotype 15A polysaccharides than the total amount of serotype 15A polysaccharides. In a preferred incarnation, the serotype 15A glycosurfactant contains approximately 25% less free serotype 15A polysaccharides than the total amount of serotype 15A polysaccharides. Glycoconuts of serotype 15A can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Larger molecules excluded from the pores in the media are rinsed more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using saccharide assay colorimetry. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In one incarnation, at least 40% of diabetic conjugates of serotype 15AKd have a CL-4B serotype less than or equal to 0.3. In a preferred incarnation, at least 50% of diabetic conjugates have a CL-4B serotype less than or equal to 0.3. In a preferred incarnation, between 50% and 90% of diabetic conjugates of serotype 15AKd have a CL-4B serotype less than or equal to 0.3. In one incarnation, a serotype 15A polysaccharide is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein (preferably CRM197). For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In a preferred embodiment, the serotype 15A glycoconjugates of the invention are prepared using amine-reductive chemistry. According to the present invention, the amine-reductive process involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate (see, for example, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the invention's serotype 15A glycoconjugates are prepared by conjugating an isolated serotype 15A capsular polysaccharide with a carrier protein through a process that includes the step: (a) Reaction of the aforementioned serotype 15A capsular polysaccharide with an oxidizing agent; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) Reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As mentioned above, prior to oxidation, the isolated serotype 15A capsular polysaccharide can be sized to a target molecular weight (MW) range. Therefore, in one incarnation, the isolated serotype 15A capsular polysaccharide is sized prior to oxidation. In one incarnation, the isolated serous-type 15A capsular polysaccharide is not sized prior to oxidation. In one embodiment, oxidation step (a) is carried out at a pH between 4.0 and 6.0. Preferably, oxidation step (a) is carried out at a pH between 4.5 and 5.5. In one of the incarnations, the oxidation step (a) is carried out at a pH of approximately 5.0. After the oxidation step (a), it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one embodiment, the serotype 15A activated polysaccharide of the present invention has a mean molecular weight (Mw) between 50 kDa and 500 kDa. In another embodiment, the mean molecular weight (Mw) ranges from 75 kDa to 250 kDa. In a preferred embodiment, the mean molecular weight (Mw) ranges from 75 kDa to 175 kDa. In a more preferred embodiment, the mean molecular weight (Mw) ranges from 90 kDa to 150 kDa. In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.1–2 molar equivalents of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.5–1.5 molar equivalents of pyridates. Even more preferably, step (a) involves the reaction of the polysaccharide with 0.8–1.2 molar equivalents of pyridates. In one embodiment, the oxidation degree (also called the "activation degree" in the current document) of the activated serotype 15A polysaccharide ranges between 2 and 20. In a preferred embodiment, the oxidation degree of the activated serotype 15A polysaccharide ranges between 2 and 8. In a more preferred embodiment, the oxidation degree of the activated serotype 15A polysaccharide is 5±2.5. In one incarnation, the activated serotype 15A polysaccharide and the activated protein are lysed before step (b). Preferably, lysing occurs after step (a). In another incarnation, the activated polysaccharide is lysed after step (a), and the carrier protein is also lysed. In one embodiment, the activated serotype 15A polysaccharide is lysed after step (a) and the carrier protein is also lysed, and the activated polysaccharide and carrier protein are reconstituted in the same solution. In one incarnation, the activated serotype 15A polysaccharide and the carrier protein are independently lyzed (separate lysing). In another incarnation, the activated serotype 15A polysaccharide and the carrier protein are lyzed together (co-lysing). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is selected from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is sucrose. In one incarnation, the initial input ratio (wt) of activated serotype 15A capsular polysaccharide to the carrier protein in step (b) ranges between 1:3 and 1:0.5. In another incarnation, the initial input ratio (wt) of activated serotype 15A capsular polysaccharide to the carrier protein ranges between 1:1.5 and 1:0.5. Preferably, the initial input ratio (wt) of activated serotype 15A capsular polysaccharide to the carrier protein in step (b) ranges between 1:1.1 and 1:0.9. In one embodiment, the reduction reaction (C) is carried out in an aqueous solvent. Ideally, the reduction reaction (C) is carried out in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). Preferably, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent or in DMF (dimethyl sulfoxide). In a more preferred manner, the reduction reaction (c) is carried out in the solvent DMSO (dimethyl sulfoxide). In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranates such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of the reducing agent are used in step (c). Preferably, between 0.5 and 2 molar equivalents of the reducing agent are used in step (c). Even more preferably, between 0.9 and 1.1 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, there are unreacted aldehyde groups remaining in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation with the carrier protein, the serotype 15A glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the serotype 15A glycoconjugate for the present invention includes a post-production purification step. 6.1 Pneumococcal serotype 23A glycosuria-specific diabetic conjugate In one aspect, the invention relates to serotype 23A glycoconjugates of Streptococcus pneumoniae. The structure of the Streptococcus pneumoniae serotype 23A polysaccharide is well-established in the art of synthesis (see, for example, Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19-29 and WO2019050814). The structure of the capsular polysaccharide of serotype 23A is: →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1→2)]-[Gro-(2→P→3)]-β-D-Galp-(1→4)]-β-L-Rhap-(1→ In one embodiment, the Streptococcus pneumoniae serotype 23A capsular polysaccharide used in the present invention is a synthetic carbohydrate. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be Streptococcus pneumoniae serotype 23A bacteria. Bacterial strains that can be used as a source of Streptococcus pneumoniae serotype 23A polysaccharide may be obtained from selected culture kits (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Polysaccharides of serotype 23A can be obtained directly from the bacteria using isolation procedures familiar to any ordinary industrialist. They can also be purchased (e.g., from the American Agriculture Printing Group (ATCC, Manassas, VA USA) (e.g., reference no. ATCC 545-X, no. ATCC 546-X, no. ATCC 547-X). If serotype 23A polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 23A capsular polysaccharides, the bacterial cells can be lysed to produce cell lysate. The serotype 23A polysaccharides can then be isolated from the cell lysate using well-established purification techniques, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 23A capsular polysaccharide can then be used to prepare glycoconjugates. The resulting serotype 23A capsular polysaccharide can be distinguished by purifying the serotype 23A polysaccharide from Streptococcus pneumoniae lysate and selectively sizing the purified polysaccharide using various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In a preferred incarnation, the isolated serotype 23A capsular polysaccharide (i.e., purified before further processing) has a mean molecular weight between 100 kDa and 2500 kDa. In one incarnation, the isolated serotype 23A capsular polysaccharide has a mean molecular weight between 250 kDa and 1500 kDa. In another incarnation, the isolated serotype 23A capsular polysaccharide has a mean molecular weight between 500 kDa and 1000 kDa. Any whole number within any of the ranges mentioned above is expected as an embodiment of the detection. To create serotype 23A conjugates with characteristic filtration, immunogenicity, and / or yield properties, the polysaccharide can be scaled to a target molecular weight range prior to conjugation with a carrier protein. Beneficially, the size of the purified serotype 23A polysaccharide is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical scaling can be employed. In a more preferable way, the size of the purified serotype 23A polysaccharide is reduced by mechanical homogenization. It was found that the use of acid hydrolysis, as recommended, for example, in WO2019050814 or in WO2019050818, is not suitable for reducing the size of the serotype 23A polysaccharide. Acid hydrolysis was found to affect the integrity of the serotype 23A polysaccharide structure. Even relatively mild hydrolysis (e.g., treatment with acetic acid at 100 mM at 80 °C for 2 hours) was found to result in a 25% loss of branched rhamnose (α-L-Rhap-(1→2)) (see Figure 1). Mechanical sizing allows for the preservation of this residue, which is crucial from an immunological perspective. Furthermore, this residue is the primary site for pyridate oxidation activation. Therefore, its preservation is essential when using pyridate oxidation of polysaccharides (such as the activation step in amine reduction chemistry). Therefore, a preferred embodiment is the reduction in the size of the serotype 23A polysaccharide purified by mechanical homogenization. In one embodiment, the size of the purified serotype 23A polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process current through a sufficiently small flow path. The shear rate increases with higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed current through the homogenizer. In a more preferred embodiment, the preparation of the invention's serotype 23A glycoconjugate does not include the step of serotype 23A polysaccharide sizing by acid hydrolysis. In one incarnation, the isolated serotype 23A capsular polysaccharide is scaled to an intermediate molecular weight between 50 kDa and 500 kDa. In a preferred incarnation, the isolated serotype 23A capsular polysaccharide is scaled to an intermediate molecular weight between 75 kDa and 400 kDa. In another preferred incarnation, the isolated serotype 23A capsular polysaccharide is scaled to an intermediate molecular weight between 100 kDa and 350 kDa. In an even more preferred incarnation, the isolated serotype 23A capsular polysaccharide is scaled to an intermediate molecular weight between 125 kDa and 225 kDa. Ideally, the isolated serotype 23A capsular polysaccharide is sized by mechanical homogenization, preferably high-pressure homogenization. In one incarnation, the isolated serotype 23A capsular polysaccharide is not scaled. In one incarnation, the preconjugated serotype 23A capsular polysaccharide has a mean molecular weight between 50 kDa and 500 kDa. In another incarnation, the preconjugated serotype 23A capsular polysaccharide has a mean molecular weight between 75 kDa and 400 kDa. In a preferred incarnation, the preconjugated serotype 23A capsular polysaccharide has a mean molecular weight between 100 kDa and 350 kDa. In an even more preferred incarnation, the preconjugated serotype 23A capsular polysaccharide has a mean molecular weight between 125 kDa and 225 kDa. The molecular weight (Mw) of the polysaccharide before conjugation refers to the molecular weight before the activation of the polysaccharide (i.e., after a final sizing step but before the polysaccharide reacts with the activating agent). In the context of the present invention, the molecular weight of polysaccharide 23A is not significantly altered by the activation step, and the molecular weight of polysaccharide 23A included in the conjugate is similar to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the serotype 23A glycosurfactant of the present invention contains a serotype 23A capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 400 kDa. In another embodiment, the average molecular weight (Mw) ranges from 100 kDa to 300 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 120 kDa to 240 kDa. In some incarnations, the invention's serotype 23A diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 10,000 kDa. In other incarnations, the serotype 23A diabetic conjugate has a mean molecular weight (Mw) between 1,000 kDa and 7,500 kDa. Ideally, the serotype 23A diabetic conjugate has a mean molecular weight (Mw) between 2,000 kDa and 5,000 kDa. The invention's serotype 23A glycoconjugates can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 23A polysaccharide-to-carrier protein ratio in the glycoconjugate (w / w) ranges from 0.5 to 3.0. Preferably, the saccharide-to-carrier protein ratio (w / w) ranges from 0.7 to 1.5. Even more preferably, the saccharide-to-carrier protein ratio (w / w) ranges from 0.8 to 1.4. Another method for distinguishing the patent serotype 23A glycoconjugates is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a range of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods known to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the initial carrier protein material used to create the conjugate material. In a preferred embodiment, the degree of conjugation of the patent serotype 23A glycoconjugate ranges from 2 to 20. In a more favorable embodiment, the degree of conjugation of the patent serotype 23A glycoconjugate ranges from 5 to 15. Serotype 23A glycoconjugates and invention-specific immunomodulatory formulations may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present in the glycoconjugate structure. The free polysaccharide may be non-covalently bound to the glycoconjugate (i.e., attached to it, adsorbed to it, or drawn into or with it). In one incarnation, the serotype 23A glycosurfactant contains approximately 40% less free serotype 23A polysaccharides compared to the total amount of serotype 23A polysaccharides. In a preferred incarnation, the serotype 23A glycosurfactant contains approximately 25% less free serotype 23A polysaccharides compared to the total amount of serotype 23A polysaccharides. Glycoconuts of serotype 23A can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Larger molecules excluded from the pores in the media are rinsed more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using saccharide assay colorimetry. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In a preferred embodiment, at least 40% of diabetic conjugates of serotype 23AKd have a CL-4B affinity less than or equal to 0.3. In a preferred embodiment, at least 50% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred embodiment, between 50% and 89% of diabetic conjugates of serotype 23AKd have a CL-4B affinity less than or equal to 0.3. Glycoconus of serotype 23A can also be distinguished by the amount of branched rhamnose residual that remains in the serotype 23A polysaccharide. As mentioned above, it has been found that the serotype 23A polysaccharide can lose the branched rhamnose residual (see Figure 1). Therefore, in one embodiment, the present invention's serotype 23A glycosuric conjugate includes a serotype 23A capsular polysaccharide in which the said serotype 23A capsular polysaccharide has a branched rhamnose content greater than 75% when compared to the serotype 23A capsular polysaccharide in which the branched rhamnose content is approximately 100%. In one embodiment, the present invention's serotype 23A pneumococcal conjugate includes a serotype 23A pneumococcal capsular polysaccharide, in which the said serotype 23A pneumococcal capsular polysaccharide has a branched rhamnose content greater than 90% when compared with the original serotype 23A pneumococcal capsular polysaccharide, in which the branched rhamnose content is approximately 100%.Preferably, the Streptococcus pneumoniae serotype 23A glycopolysaccharide (SPPC) of the present invention includes a Streptococcus pneumoniae serotype 23A capsular polysaccharide with a branched rhamnose content greater than 95% when compared with the original Streptococcus pneumoniae serotype 23A capsular polysaccharide with a branched rhamnose content of approximately 100%. In a more preferred embodiment, the present invention's serotype 23A pneumococcal conjugate includes a serotype 23A pneumococcal capsular polysaccharide, of which the said serotype 23A pneumococcal capsular polysaccharide has a branched rhamnose content of approximately 100% when compared with the original serotype 23A pneumococcal capsular polysaccharide, of which the branched rhamnose content is approximately 100%. In one incarnation, the serotype 23A polysaccharide is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein (preferably CRM197). For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In a preferred embodiment, the serotype 23A glycoconjugates of the invention are prepared using amine-reductive chemistry. According to the present invention, the amine-reductive process involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate (see, for example, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the invention's serotype 23A glycoconjugates are prepared by conjugating an isolated serotype 23A capsular polysaccharide with a carrier protein through a process that includes the following step: (a) Reaction of the aforementioned serotype 23A capsular polysaccharide with an oxidizing agent; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) Reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As mentioned above, prior to oxidation, the isolated serotype 23A capsular polysaccharide can be sized to a target molecular weight (MW) range. Therefore, in one incarnation, the isolated serotype 23A capsular polysaccharide is sized prior to oxidation. In one preferred embodiment, the isolated serotype 23A capsular polysaccharide is reduced in size by mechanical homogenization. In another embodiment, the isolated serotype 23A capsular polysaccharide is reduced in size by high-pressure homogenization. In a more preferred embodiment, the isolated serotype 23A capsular polysaccharide is not reduced in size by acid hydrolysis. In one incarnation, the isolated serous-type 23A capsular polysaccharide is not sized prior to oxidation. In one embodiment, oxidation step (a) is carried out at a pH between 4.5 and 6.5. Preferably, oxidation step (a) is carried out at a pH between 5.0 and 6.0. In one of the incarnations, the oxidation step (a) is carried out at a pH of approximately 5.0. After the oxidation step (a), it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one embodiment, the serotype 23A activated polysaccharide of the present invention has a mean molecular weight (Mw) between 50 kDa and 400 kDa. In another embodiment, the mean molecular weight (Mw) ranges between 100 kDa and 250 kDa. In a more preferred embodiment, the mean molecular weight (Mw) ranges between 120 kDa and 200 kDa. In one incarnation, the serotype 23A polysaccharide of the current invention retains at least 80% of the branched ribose. In another incarnation, the serotype 23A polysaccharide of the current invention retains at least 85% of the branched ribose. In yet another incarnation, the serotype 23A polysaccharide of the current invention retains at least 90% of the branched ribose. In another incarnation, the serotype 23A polysaccharide of the current invention retains at least 95% of the branched ribose. In a preferred embodiment, the serotype 23A activated polysaccharide of the present invention retains at least 96% of the branched ribose. In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.1–2 molar equivalents of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.2–1.5 molar equivalents of pyridates. Even more preferably, step (a) involves the reaction of the polysaccharide with 0.3–0.6 molar equivalents of pyridates. In one embodiment, the oxidation degree (also called the "activation degree" in the present document) of the activated serotype 23A polysaccharide ranges between 2 and 20. In a preferred embodiment, the oxidation degree of the activated serotype 23A polysaccharide ranges between 2 and 8. In a more preferred embodiment, the oxidation degree of the activated serotype 23A polysaccharide is 5±2.5. In one incarnation, the activated serotype 23A polysaccharide and the activated protein are lysed before step (b). Preferably, lysing occurs after step (a). In another incarnation, the activated polysaccharide is lysed after step (a), and the carrier protein is also lysed. In one embodiment, the activated serotype 23A polysaccharide is lysed after step (a) and the carrier protein is also lysed, and the activated polysaccharide and carrier protein are reconstituted in the same solution. In one incarnation, the activated serotype 23A polysaccharide and the carrier protein are independently lyzed (separate lysing). In another incarnation, the activated serotype 23A polysaccharide and the carrier protein are lyzed together (co-lysing). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is selected from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is sucrose. In one incarnation, the initial (wt) insertion ratio of activated serotype 23A capsular polysaccharide to the carrier protein in step (b) ranges between 1:2 and 1:0.5. In another incarnation, the initial (wt) insertion ratio of activated serotype 23A capsular polysaccharide to the carrier protein ranges between 1:1.2 and 1:0.6. Ideally, the initial (wt) insertion ratio of activated serotype 23A capsular polysaccharide to the carrier protein ranges between 1:0.9 and 1:0.7. In one embodiment, reduction reaction (C) is carried out in an aqueous solvent. Preferably, reduction reaction (C) is carried out in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). Preferably, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent or in DMF (dimethyl sulfoxide). In a more preferred manner, the reduction reaction (c) is carried out in the solvent DMSO (dimethyl sulfoxide). In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium, or zinc borohydride in the presence of Bronsted or Lewis acids, such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of the reducing agent are used in step (c). Ideally, between 0.2 and 1.5 molar equivalents of the reducing agent are used in step (c). Even more ideally, between 0.5 and 1.0 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, there are unreacted aldehyde groups remaining in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation with the carrier protein, the serotype 23A glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the serotype 23A glycoconjugate for the present invention includes a post-production purification step. 7.1 The invention-specific diabetic conjugate of serotype 23B of Streptococcus pneumoniae In one respect, the reduction relates to glycoconjugates of serotype 23B of Streptococcus pneumoniae. The structure of the Streptococcus pneumoniae serotype 23B polysaccharide is well-established in the art of synthesis (see, for example, Ravenscroft N et al. (2017) Carbohydrate Res. Vol. 450, p 19–29 and WO2019050814). The structure of the capsular polysaccharide of serotype 23B is: →4)-β-D-Glcp-(1→4)-[Gro-(2→P→3)]- β-D-Galp-(1→4)- β-L-Rhap-(1→. In one embodiment, the Streptococcus pneumoniae serotype 23B capsular polysaccharide used in the present invention is a synthetic carbohydrate. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be Streptococcus pneumoniae serotype 23B bacteria. Bacterial strains suitable as a source of Streptococcus pneumoniae serotype 23B polysaccharide may be obtained from selected culture collections (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Polysaccharides of serotype 23B can be obtained directly from the bacteria using isolation procedures known to any ordinary industrial technician. They can also be purchased (e.g., from the American Agriculture Printing Group (ATCC, Manassas, VA USA) (e.g., reference no. ATCC 548-X, no. ATCC 549-X, no. ATCC 550-X). If serotype 23B polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 23B capsule polysaccharides, the bacterial cells can be lysed to produce cell lysate. The serotype 23B polysaccharides can then be isolated from the cell lysate using well-established purification techniques, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 23B capsule polysaccharide can then be used to prepare glycoconjugates. The resulting serotype 23B capsular polysaccharide can be distinguished by purifying the serotype 23B polysaccharide from Streptococcus pneumoniae lysate and selectively sizing the purified polysaccharide using various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In a preferred incarnation, the isolated serotype 23B capsular polysaccharide (i.e., purified before further processing) has a mean molecular weight between 100 kDa and 2500 kDa. In one incarnation, the isolated serotype 23B capsular polysaccharide has a mean molecular weight between 250 kDa and 2000 kDa. In another incarnation, the isolated serotype 23B capsular polysaccharide has a mean molecular weight between 300 kDa and 1000 kDa. Any whole number within any of the ranges mentioned above is expected as an embodiment of the detection. To create serotype 23B conjugates with specific filtration, immunogenicity, and / or yield properties, the polysaccharide can be scaled to a target molecular weight range prior to conjugation with a carrier protein. Beneficially, the size of the purified serotype 23B polysaccharide is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical scaling can be employed. In one of the incarnations, the volume of the purified serotype 23B polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis can be performed using a dilute acid (e.g., acetic acid, formic acid, propanoic acid). Alternatively, chemical hydrolysis can be performed using a dilute strong acid (e.g., dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid, or dilute perchloric acid). Ideally, the size of purified serotype 23B polysaccharides is reduced by mechanical homogenization. In one embodiment, the size of purified serotype 23B polysaccharides is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate increases with higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed stream through the homogenizer. In one embodiment, the isolated serotype 23B capsular polysaccharide is sized to an intermediate molecular weight between 50 kDa and 750 kDa. In a preferred embodiment, the isolated serotype 23B capsular polysaccharide is sized to an intermediate molecular weight between 75 kDa and 400 kDa. In another preferred embodiment, the isolated serotype 23B capsular polysaccharide is sized to an intermediate molecular weight between 100 kDa and 250 kDa. Ideally, the isolated serotype 23B polysaccharide is sized by mechanical homogenization, preferably high-pressure homogenization. In one incarnation, the isolated serotype 23B capsular polysaccharide is not scaled. In one incarnation, the preconjugated serotype 23B capsular polysaccharide has an average molecular weight between 50 kDa and 750 kDa. In another incarnation, the preconjugated serotype 23B capsular polysaccharide has an average molecular weight between 75 kDa and 400 kDa. In a preferred incarnation, the preconjugated serotype 23B capsular polysaccharide has an average molecular weight between 100 kDa and 250 kDa. The molecular weight (Mw) of the polysaccharide before conjugation refers to the molecular weight before the activation of the polysaccharide (i.e., after the final sizing step but before the reaction of the polysaccharide with the activating agent). In the context of the present invention, the molecular weight of polysaccharide 23B is not substantially modified by the activation step, and the molecular weight of polysaccharide 23B included in the conjugate is similar to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the serotype 23B glycosurfactant of the present invention contains a serotype 23B capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 40 kDa to 600 kDa. In another embodiment, the average molecular weight (Mw) ranges from 50 kDa to 300 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 100 kDa to 200 kDa. In some incarnations, the invention's serotype 23B diabetic conjugate has a mean molecular weight (Mw) between 250 kDa and 7,500 kDa. In other incarnations, the serotype 23B diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 4,000 kDa. Ideally, the serotype 23B diabetic conjugate has a mean molecular weight (Mw) between 700 kDa and 2,000 kDa. The invention's serotype 23B glycoconjugates can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 23B glycoconjugate-to-carrier protein ratio (w / w) ranges from 0.4 to 3.0. Ideally, the saccharide-to-carrier protein ratio (w / w) ranges from 0.5 to 1.5. Even more ideally, the saccharide-to-carrier protein ratio (w / w) ranges from 0.6 to 1.3. Another method for distinguishing the patent serotype 23B glycoconjugates is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a band of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods known to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the carrier protein precursor used to create the conjugate material. In a preferred embodiment, the degree of conjugation of the patent serotype 23B glycoconjugate ranges from 2 to 15. In a more favorable embodiment, the degree of conjugation of the patent serotype 23B glycoconjugate ranges from 5 to 12. Serotype 23B glycoconjugates and invention-specific immunomodulatory constructs may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present in the glycoconjugate structure. The free polysaccharide may be non-covalently bound to the glycoconjugate (i.e., attached to it, adsorbed to it, or drawn into or with it). In one incarnation, the serotype 23B diabetic conjugate contains approximately 40% less free serotype 23B polysaccharides compared to the total amount of serotype 23B polysaccharides. In a preferred incarnation, the serotype 23B diabetic conjugate contains approximately 25% less free serotype 23B polysaccharides compared to the total amount of serotype 23B polysaccharides. Glycoconuts of serotype 23B can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Larger molecules excluded from the pores in the media are rinsed more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In one incarnation, at least 30% of diabetic conjugates of serotype 23BKd have a CL-4B affinity ≤ 0.3. In a preferred incarnation, at least 35% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred incarnation, between 40% and 60% of diabetic conjugates of serotype 23BKd have a CL-4B affinity ≤ 0.3. In one incarnation, the polysaccharide of serotype 23B is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein (preferably CRM197). For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In a preferred embodiment, the serotype 23B glycoconjugates of the invention are prepared using amine-reductive chemistry. According to the present invention, the amine-reductive process involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate (see, for example, WO2006 / 110381, WO2008 / 079653, WO2008 / 143709, WO2008 / 079732, WO2011 / 110531, WO2012 / 119972, WO2015110941, WO2015110940, WO2018 / 144439, WO2018 / 156491). In one embodiment, the invention's serotype 23B glycoconjugates are prepared by conjugating an isolated serotype 23B capsular polysaccharide with a carrier protein through a process that includes the step: (a) Reaction of the aforementioned serotype 23B capsular polysaccharide with an oxidizing agent; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) Reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As mentioned above, prior to oxidation, the isolated serotype 23B capsular polysaccharide can be sized to a target molecular weight (MW) range. Therefore, in one incarnation, the isolated serotype 23B capsular polysaccharide is sized prior to oxidation. In one preferred embodiment, the size of the encapsulated polysaccharide of serotype 23B isolated is reduced by mechanical homogenization. In another embodiment, the size of the isolated serotype 23B polysaccharide is reduced by high-pressure homogenization. In one incarnation, the isolated serous-type 23B capsular polysaccharide is not sized prior to oxidation. In one embodiment, oxidation step (a) is carried out at a pH between 4.0 and 6.5. Preferably, oxidation step (a) is carried out at a pH between 4.5 and 5.5. In one of the incarnations, the oxidation step (a) is carried out at a pH of approximately 5.0. After the oxidation step (a), it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one incarnation, the serotype 23B activated polysaccharide of the present invention has a mean molecular weight (Mw) between 40 kDa and 600 kDa. In another incarnation, the mean molecular weight (Mw) ranges between 50 kDa and 300 kDa. In a more preferred incarnation, the mean molecular weight (Mw) ranges between 100 kDa and 200 kDa. In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.05–1 molar equivalent of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.1–0.3 molar equivalents of pyridates. Even more preferably, step (a) involves the reaction of the polysaccharide with approximately 0.2 molar equivalents of pyridates. In one incarnation, the oxidation degree (also called "activation degree" in the present document) of the activated serotype 23B polysaccharide ranges between 2 and 20. In a preferred incarnation, the oxidation degree of the activated serotype 23B polysaccharide ranges between 4 and 15. In a more preferred incarnation, the oxidation degree of the activated serotype 23B polysaccharide is 9±3. In one incarnation, the activated serotype 23B polysaccharide and the carrier protein are lysed before step (b). Preferably, lysing occurs after step (a). In another incarnation, the activated polysaccharide is lysed after step (a), and the carrier protein is also lysed. In one embodiment, the activated serotype 23B polysaccharide is lysed after step (a) and the carrier protein is also lysed, and the activated polysaccharide and carrier protein are reconstituted in the same solution. In one incarnation, the activated serotype 23B polysaccharide and the carrier protein are independently lyzed (separate lysing). In another incarnation, the activated serotype 23B polysaccharide and the carrier protein are lyzed together (co-lysing). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is selected from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is sucrose. In one incarnation, the initial (wt) insertion ratio of activated serotype 23B capsular polysaccharide to carrier protein in step (b) ranges between 1:2 and 1:0.5. Ideally, the initial (wt) insertion ratio of activated serotype 23B capsular polysaccharide to carrier protein ranges between 1:1.2 and 1:0.6. Ideally, the initial (wt) insertion ratio of activated serotype 23B capsular polysaccharide to carrier protein ranges between 1:0.9 and 1:0.7. In one embodiment, the reduction reaction (C) is carried out in an aqueous solvent. Ideally, the reduction reaction (C) is carried out in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). Preferably, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent or in DMF (dimethyl sulfoxide). In a more preferred manner, the reduction reaction (c) is carried out in the solvent DMSO (dimethyl sulfoxide). In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranates such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of the reducing agent are used in step (c). Ideally, between 0.5 and 1.5 molar equivalents of the reducing agent are used in step (c). Even more ideally, between 0.9 and 1.1 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, there are unreacted aldehyde groups remaining in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation with the carrier protein, the serotype 23B glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the serotype 23B glycoconjugate for the present invention includes a post-production purification step. 8.1 The invention-specific serotype 24F diabetic conjugate of Streptococcus pneumoniae In one aspect, the invention relates to serotype 24F glycoconjugates of Streptococcus pneumoniae. The construction of the 24F serotype polysaccharide of Streptococcus pneumoniae is well-known in the art of the industry (see, for example, WO2019050815). In one embodiment, the serotype 24F capsular polysaccharide of Streptococcus pneumoniae used in the present invention is a synthetic carbohydrate. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be Streptococcus pneumoniae serotype 24F bacterial cells. Bacterial strains suitable as a source of Streptococcus pneumoniae serotype 24F polysaccharide may be obtained from selected culture kits (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Polysaccharides of serotype 24F can be obtained from bacteria using isolation procedures familiar to any ordinary skilled technician. They can also be purchased (e.g., from the American Agriculture Printing Group (ATCC, Manassas, VA USA) (e.g., reference no. ATCC 551-X, no. ATCC 552-X, no. ATCC 553-X). If serotype 24F polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 24F capsule polysaccharides, the bacterial cells can be lysed to produce cell lysate. The serotype 24F polysaccharides can then be isolated from the cell lysate using well-established purification techniques, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 24F capsular polysaccharide can then be used to prepare glycoconjugates. The resulting serotype 24F capsular polysaccharide can be distinguished by purifying the serotype 24F polysaccharide from Streptococcus pneumoniae lysate and selectively sizing the purified polysaccharide using various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In a preferred incarnation, the isolated serotype 24F capsular polysaccharide (i.e., purified after further processing) has a mean molecular weight between 100 kDa and 2500 kDa. In one incarnation, the isolated serotype 24F capsular polysaccharide has a mean molecular weight between 250 kDa and 2000 kDa. In another incarnation, the isolated serotype 24F capsular polysaccharide has a mean molecular weight between 500 kDa and 1000 kDa. Any complete integer within any of the ranges mentioned above is expected as an embodiment of the detection. To create serotype 24F conjugates with specific filtration, immunogenicity, and / or yield properties, the polysaccharide can be scaled to a target molecular weight range prior to conjugation with a carrier protein. Beneficially, the size of the purified serotype 24F polysaccharide is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical scaling can be employed. In a more preferable way, the size of the purified serotype 24F polysaccharide is reduced by mechanical homogenization. It was found that the use of acid hydrolysis, as recommended, for example, in WO2019050815 or in WO2019050818, is not suitable for reducing the size of the serotype 24F polysaccharide. Acid hydrolysis was found to affect the integrity of the serotype 24F polysaccharide structure. Even relatively mild hydrolysis (e.g., treatment with acetic acid at 100 mM at 80 °C for about 2 hours) was found to result in a 25% loss of branched ribose retarders (see Figure 2). Mechanical sizing allows for the non-loss of this underdeveloped tissue, which is important from an immunological point of view. Therefore, in a preferred embodiment, the size of the purified serotype 24F polysaccharide is reduced by mechanical homogenization. In one embodiment, the size of the purified serotype 24F polysaccharide is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate increases with higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed stream through the homogenizer. In a more preferred embodiment, the preparation of the invention's serotype 24F glycoconjugate does not include the step of serotype 24F polysaccharide sizing by acid hydrolysis. In one incarnation, the isolated serotype 24F capsular polysaccharide is scaled to an intermediate molecular weight between 50 kDa and 500 kDa. In a preferred incarnation, the isolated serotype 24F capsular polysaccharide is scaled to an intermediate molecular weight between 75 kDa and 400 kDa. In another preferred incarnation, the isolated serotype 24F capsular polysaccharide is scaled to an intermediate molecular weight between 125 kDa and 275 kDa. In an even more preferred incarnation, the isolated serotype 24F capsular polysaccharide is scaled to an intermediate molecular weight between 125 kDa and 225 kDa. Preferably, the isolated serotype 24F polysaccharide is sized by mechanical homogenization, and even more preferably by high-pressure homogenization. In one incarnation, the isolated serotype 24F capsular polysaccharide is not scaled. In one incarnation, the preconjugated serotype 24F capsular polysaccharide has a mean molecular weight between 50 kDa and 500 kDa. In another incarnation, the preconjugated serotype 24F capsular polysaccharide has a mean molecular weight between 75 kDa and 400 kDa. In a preferred incarnation, the preconjugated serotype 24F capsular polysaccharide has a mean molecular weight between 125 kDa and 275 kDa. In an even more preferred incarnation, the preconjugated serotype 24F capsular polysaccharide has a mean molecular weight between 125 kDa and 225 kDa. The molecular weight (Mw) of the polysaccharide before conjugation refers to the molecular weight before the activation of the polysaccharide (i.e., after a final sizing step but before the polysaccharide reacts with an activating agent). In the context of the present invention, the molecular weight of the 24F polysaccharide is not substantially altered by the activation step, and the molecular weight of the 24F polysaccharide included in the conjugate is identical to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the serotype 24F glycosurfactant of the present invention contains a serotype 24F capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 400 kDa. In another embodiment, the average molecular weight (Mw) ranges from 120 kDa to 250 kDa. In a more preferred embodiment, the average molecular weight (Mw) ranges from 120 kDa to 200 kDa. In some incarnations, the invention's serotype 24F glycosurfactant has a mean molecular weight between 500 kDa and 10,000 kDa. In other incarnations, the invention's serotype 24F glycosurfactant has a mean molecular weight between 1,500 kDa and 7,500 kDa. Ideally, the invention's serotype 24F glycosurfactant has a mean molecular weight between 3,000 kDa and 6,000 kDa. The invention's serotype 24F glycoconjugates can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 24F glycoconjugate's (w / w) glycoconjugate ratio ranges from 0.5 to 3.0. Ideally, the saccharide-to-carrier protein (w / w) ratio ranges from 0.7 to 1.5. Even more ideally, the saccharide-to-carrier protein (w / w) ratio ranges from 0.8 to 1.4. Another method for distinguishing the patent serotype 24F glycoconjugates is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a band of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods familiar to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the initial carrier protein material used to construct the conjugate material. In a preferred embodiment, the degree of conjugation of the patent serotype 24F glycoconjugate ranges from 2 to 15. In a more favorable embodiment, the degree of conjugation of the patent serotype 24F glycoconjugate ranges from 5 to 12. Serotype 24F glycoconjugates and invention-specific immunomodulatory formulations may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present in the glycoconjugate structure. The free polysaccharide may be non-covalently bound to the glycoconjugate (i.e., attached to it, adsorbed to it, or drawn into or with it). In one incarnation, the serotype 24F glycosurfactant contains approximately 40% less free serotype 24F polysaccharides compared to the total amount of serotype 24F polysaccharides. In a preferred incarnation, the serotype 24F glycosurfactant contains approximately 25% less free serotype 24F polysaccharides compared to the total amount of serotype 24F polysaccharides. Glycoconuts of serotype 24F can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Larger molecules excluded from the pores in the media are rinsed more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In a preferred embodiment, at least 40% of diabetic conjugates of serotype 24FKd have a CL-4B affinity less than or equal to 0.3. In a preferred embodiment, at least 50% of diabetic conjugates have a CL-4B affinity less than or equal to 0.3. In a preferred embodiment, between 50% and 90% of diabetic conjugates of serotype 24FKd have a CL-4B affinity less than or equal to 0.3. Glycoconus of serotype 24F can also be distinguished by the amount of branched ribose residual remaining in the 24F polysaccharide. As mentioned above, it has been found that serotype 24F polysaccharides can lose the branched ribose residual (see Figure 7). Therefore, in one embodiment, the present invention's serotype 24F glycosuric conjugate includes a serotype 24F capsular polysaccharide, where the said serotype 24F capsular polysaccharide has a ribose content greater than 75% when compared to the serotype 24F capsular polysaccharide, where the ribose content is approximately 100%. In one embodiment, the present invention's serotype 24F glycopolysaccharide includes a serotype 24F capsular polysaccharide, which has a ribose content greater than 90% when compared to the original serotype 24F capsular polysaccharide, which has a ribose content of approximately 100%.Preferably, the serotype 24F glycosuric conjugate of the present invention includes a serotype 24F glycosuric polysaccharide in which the said serotype 24F glycosuric polysaccharide has a ribose content greater than 95% when compared to the original serotype 24F glycosuric polysaccharide in which the ribose content is approximately 100%. In a more preferred embodiment, the present invention's serotype 24F pneumococcal conjugate includes a serotype 24F pneumococcal capsular polysaccharide, of which the said serotype 24F pneumococcal capsular polysaccharide has a ribose content of approximately 100% when compared to the original serotype 24F pneumococcal capsular polysaccharide, of which the ribose content is approximately 100%. In one incarnation, the serotype 24F polysaccharide is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein (preferably CRM197). For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In a preferred embodiment, the 24F serotype glycoconjugates of the invention are prepared using amine-reductive chemistry. According to the present invention, amine-reductive chemistry involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate. In one embodiment, the invention's serotype 24F glycoconjugates are prepared by conjugating an isolated serotype 24F capsular polysaccharide with a carrier protein by a process that includes the following steps: (a) reaction of the said isolated serotype 24F capsular polysaccharide with an oxidizing agent; (b) synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. As mentioned above, prior to oxidation, the isolated serotype 24F capsular polysaccharide can be sized to a target molecular weight (MW) range. Therefore, in one incarnation, the isolated serotype 24F capsular polysaccharide is sized prior to oxidation. In one preferred embodiment, the isolated serotype 24F capsular polysaccharide is reduced in size by mechanical homogenization. In another embodiment, the isolated serotype 24F capsular polysaccharide is reduced in size by high-pressure homogenization. In a more preferred embodiment, the isolated serotype 24F capsular polysaccharide is not reduced in size by acid hydrolysis. In one incarnation, the isolated serotype 24F capsular polysaccharide is not sized prior to oxidation. In one embodiment, oxidation step (a) is carried out at a pH between 4.5 and 6.5. Preferably, oxidation step (a) is carried out at a pH between 5.0 and 6.0. In one of the incarnations, the oxidation step (a) is carried out at a pH of approximately 5.0. After the oxidation step (a), it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one incarnation, the 24F serotype activated polysaccharide of the present invention has a mean molecular weight (Mw) between 50 kDa and 400 kDa. In another incarnation, the mean molecular weight (Mw) ranges between 120 kDa and 250 kDa. In a more preferred incarnation, the mean molecular weight (Mw) ranges between 120 kDa and 200 kDa. In one incarnation, the serotype 24F polysaccharide of the current invention retains at least 75% of the branched ribose. In another incarnation, the serotype 24F polysaccharide of the current invention retains at least 90% of the branched ribose. In a preferred incarnation, the serotype 24F polysaccharide of the current invention retains at least 95% of the branched ribose. In a more preferred embodiment, the 24F serotype polysaccharide of the present invention retains approximately 100% of the branched ribose. In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.1–2 molar equivalents of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.5–1.5 molar equivalents of pyridates. Even more preferably, step (a) involves the reaction of the polysaccharide with 0.9–1.1 molar equivalents of pyridates. In one incarnation, the oxidation degree (also called "activation degree" in the present document) of the activated serotype 24F polysaccharide ranges between 2 and 20. In a preferred incarnation, the oxidation degree of the activated serotype 24F polysaccharide ranges between 4 and 15. In a more preferred incarnation, the oxidation degree of the activated serotype 24F polysaccharide is 9±3. In one incarnation, the activated serotype 24F polysaccharide and the carrier protein are lysed before step (b). Preferably, lysing occurs after step (a). In another incarnation, the activated polysaccharide is lysed after step (a), and the carrier protein is also lysed. In one embodiment, the activated serotype 24F polysaccharide is lysed after step (a) and the carrier protein is also lysed, and the activated polysaccharide and carrier protein are reconstituted in the same solution. In one incarnation, the activated serotype 24F polysaccharide and the carrier protein are independently lyzed (separate lysing). In another incarnation, the activated serotype 24F polysaccharide and the carrier protein are lyzed together (co-lysing). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is selected from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is sucrose. In one incarnation, the initial (wt) insertion ratio of activated serotype 24F capsular polysaccharide to the carrier protein in step (b) ranges between 1:2 and 1:0.5. In another incarnation, the initial (wt) insertion ratio of activated serotype 24F capsular polysaccharide to the carrier protein ranges between 1:1.2 and 1:0.6. Ideally, the initial (wt) insertion ratio of activated serotype 24F capsular polysaccharide to the carrier protein ranges between 1:0.9 and 1:0.7. In one embodiment, the reduction reaction (C) is carried out in an aqueous solvent. Ideally, the reduction reaction (C) is carried out in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). Preferably, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent or in DMF (dimethylformamide). In a more preferred manner, the reduction reaction (c) is carried out in the solvent DMSO (dimethyl sulfoxide). In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranates such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of the reducing agent are used in step (c). Ideally, between 0.5 and 2.5 molar equivalents of the reducing agent are used in step (c). Even more ideally, between 1.5 and 2.5 molar equivalents of the reducing agent are used in step (c). In one of the incarnations, approximately 2 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, there are unreacted aldehyde groups remaining in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. In one embodiment, coating is achieved by mixing the product of step (c) with approximately 2 molar equivalents of sodium borohydride. After conjugation with the carrier protein, the serotype 24F glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the serotype 24F glycoconjugate for the present invention includes a post-production purification step. 9.1 The invention-specific diabetic conjugate of serotype 35B of Streptococcus pneumoniae In one aspect, the invention relates to serotype 23B glycoconjugates of Streptococcus pneumoniae. The construction of the Streptococcus pneumoniae serotype 35B polysaccharide is well known in the art of the industry (see, for example, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the serotype 35B capsular polysaccharide of Streptococcus pneumoniae used in the present invention is a synthetic carbohydrate. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be Streptococcus pneumoniae serotype 35B bacterial cells. Bacterial strains suitable as a source of Streptococcus pneumoniae serotype 35B polysaccharide may be obtained from selected culture kits (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Polysaccharides of serotype 35B can be obtained from bacteria using isolation procedures known to any ordinary skilled technician. They can also be purchased (e.g., from the American Agriculture Printing Group (ATCC, Manassas, VA USA) (e.g., reference no. ATCC 539-X, no. ATCC 540-X, no. ATCC 541-X). If serotype 35B polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 35B capsule polysaccharides, the bacterial cells can be lysed to produce cell lysate. The serotype 35B polysaccharides can then be isolated from the cell lysate using well-established purification techniques, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, WO2008 / 118752, and WO2020170190). The purified serotype 24F capsular polysaccharide can then be used to prepare glycoconjugates. The resulting serotype 35B capsular polysaccharide can be distinguished by purifying the serotype 35B polysaccharide from Streptococcus pneumoniae lysate and selectively sizing the purified polysaccharide using various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In a preferred incarnation, the isolated serotype 35B capsular polysaccharide (i.e., purified after further processing) has a mean molecular weight between 100 kDa and 5000 kDa. In one incarnation, the isolated serotype 35B capsular polysaccharide has a mean molecular weight between 300 kDa and 2000 kDa. In another incarnation, the isolated serotype 35B capsular polysaccharide has a mean molecular weight between 500 kDa and 1000 kDa. Any whole number within any of the ranges mentioned above is expected as an embodiment of the detection. The size of purified serotype 35B polysaccharides can be reduced while preserving the essential features of polysaccharide structure. Mechanical or chemical sizing can be used. Furthermore, it was found that the serotype 35B polysaccharide of Streptococcus pneumoniae undergoes cleavage during activation with pyridates, the conventional oxidizing agent used in the commonly employed amine reduction process. Pyridate oxidation appears to occur on the main chain of the serotype 35B polysaccharide, resulting in the cleavage of mannitol or ribitol and consequently a reduction in its size. Pyridate activation results in a decrease in the molecular weight of the polysaccharide. Therefore, when pyridate activation is used, the encapsulated serotype 35B polysaccharide is not sized. Therefore, in one incarnation, the capsular polysaccharide of serotype 35B is not scaled. In one incarnation, the preconjugated serotype 35B capsular polysaccharide has a mean molecular weight between 100 kDa and 5,000 kDa. In another incarnation, the preconjugated serotype 35B capsular polysaccharide has a mean molecular weight between 300 kDa and 2,000 kDa. In a more preferred incarnation, the preconjugated serotype 35B capsular polysaccharide has a mean molecular weight between 500 kDa and 1,000 kDa. The molecular weight (Mw) of a polysaccharide before conjugation refers to the molecular weight before the activation of the polysaccharide (i.e., before the polysaccharide reacts with an activating agent). In one embodiment, the serotype 35B glycosuric conjugate of the present invention includes a serotype 35B capsular polysaccharide with a mean molecular weight (Mw) between 15 kDa and 100 kDa. In another embodiment, the mean molecular weight (Mw) ranges between 25 kDa and 50 kDa. In a more preferred embodiment, the mean molecular weight (Mw) ranges between approximately 30 kDa and approximately 40 kDa. In some incarnations, the invention's serotype 35B diabetic conjugate has a mean molecular weight (Mw) between 250 kDa and 7,500 kDa. In other incarnations, the serotype 35B diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 5,000 kDa. Ideally, the serotype 35B diabetic conjugate has a mean molecular weight (Mw) between approximately 1,000 kDa and 4,000 kDa. The serotype 35B glycoconjugates of the invention can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 35B polysaccharide-to-carrier protein ratio in the glycoconjugate (w / w) ranges from 0.4 to 3.0. Ideally, the saccharide-to-carrier protein ratio (w / w) ranges from 0.4 to 2.0. Even more ideally, the saccharide-to-carrier protein ratio (w / w) ranges from 0.5 to 1.5. Another method for distinguishing the patent serotype 35B glycoconjugates is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or TT) that become conjugated with the polysaccharide, which can be distinguished as a band of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods familiar to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the initial carrier protein material used to construct the conjugate material. In a preferred embodiment, the degree of conjugation of the patent serotype 35B glycoconjugate ranges from 2 to 15. In a more favorable embodiment, the degree of conjugation of the patent serotype 35B glycoconjugate ranges from 5 to 10. Serotype 35B glycoconjugates and invention-specific immunomodulatory constructs may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present in the glycoconjugate structure. The free polysaccharide may be non-covalently bound to the glycoconjugate (i.e., attached to it, adsorbed to it, or drawn into or with it). In one incarnation, the serotype 35B diabetic conjugate includes approximately 40% less free serotype 35B polysaccharides compared to the total amount of serotype 35B polysaccharides. In another incarnation, the serotype 35B diabetic conjugate includes approximately 20% less free serotype 35B polysaccharides compared to the total amount of serotype 35B polysaccharides. In a preferred incarnation, the serotype 35B diabetic conjugate includes approximately 10% less free serotype 35B polysaccharides compared to the total amount of serotype 35B polysaccharides. Glycoconuts of serotype 35B can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Larger molecules excluded from the pores in the media are rinsed more rapidly than smaller molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the columns are calibrated to establish a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In a preferred embodiment, at least 40% of diabetic conjugates of serotype 35BKd have a CL-4B affinity ≤ 0.3. In a preferred embodiment, at least 60% of diabetic conjugates have a CL-4B affinity ≤ 0.3. In a preferred embodiment, between 50% and 80% of diabetic conjugates of serotype 35BKd have a CL-4B affinity ≤ 0.3. In one incarnation, the serotype 35B polysaccharide is activated using 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activated polysaccharide is then conjugated, either directly or via a spacer group (linker), to an amino group on the carrier protein. For example, the spacer could be cystamine or cysteamine to give a thiol-treated polysaccharide that can be conjugated to the carrier via a thioether linkage resulting after reaction with a maleimide-activated carrier protein (e.g., using N-[γ-malemidobutyroloxy]succinimide ester (GMBS)) or a haloacetyl-treated carrier protein (e.g., using iodoacetamide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4-iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB), N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]propionate (SBAP)).Preferably, the cyanate ester is conjugated to either diamine hexane or adipic acid dihydrazide (ADH), and the resulting amino-derived polysaccharide is conjugated to the carrier protein (e.g., CRM197) using carbodiimide chemistry (e.g., EDAC or EDC) via a carboxyl group on the protein carrier. Such conjugates are described, for example, in WO 93 / 15760, WO 95 / 08348, and WO 96 / 129094. Other suitable conjugation techniques utilize carbodiides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, and TSTU. Many of these are described in International Patent Application Publication No. WO 98 / 42721. Conjugation may involve a carbonyl linkage, which can be formed by the reaction of a free hydroxyl group of the saccharide with 1,1ˊ-carbonyldimidazole (CDI) (see Bethell et al. (1979) J. Biol. Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518), followed by reaction with a protein to form a carbamate bond. This may involve reduction of the carbonyl isomer end to a primary hydroxyl group, selective protection / deprotection of the primary hydroxyl group, reaction of the primary hydroxyl group with CDI to form a CDI carbamate intermediate, and coupling of the CDI carbamate intermediate to an amino group present on a protein. In a preferred embodiment, the serotype 35B glycoconjugates of the invention are prepared using amine-reductive chemistry. According to the present invention, amine-reductive chemistry involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein to form a glycoconjugate. In one embodiment, the invention's serotype 35B glycoconjugates are prepared by conjugating an isolated serotype 35B capsular polysaccharide with a carrier protein by a process that includes the following steps: (a) reaction of the said isolated serotype 35B capsular polysaccharide with an oxidizing agent; (b) synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. Preferably, the isolated serous-type 35B capsular polysaccharide is not sized prior to oxidation. In a preferred embodiment, step (a) is quenched by adding a quenching agent to stop oxidation. Therefore, in a preferred embodiment, the invention's serotype 35B glycoconjugates are prepared by conjugating an isolated serotype 35B capsular polysaccharide with a carrier protein through a process that includes the following steps: (a) reaction of the said isolated serotype 35B capsular polysaccharide with an oxidizing agent; (aˊ) quenching of the oxidation reaction by adding a quenching agent resulting from an activated serotype 35B capsular polysaccharide; (b) synthesis of the activated polysaccharide from step (aˊ) with a carrier protein; and (c) reaction of the synthesized activated polysaccharide and carrier protein with a reducing agent to form a glycoconjugate. In one embodiment, oxidation step (a) is carried out at a pH between 5.0 and 7.0. Preferably, oxidation step (a) is carried out at a pH between 5.5 and 6.5. In one of the incarnations, the oxidation step (a) is carried out at a pH of approximately 6.0. After the (a)-(aˊ) oxidation step, it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one preferred incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another preferred incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.05–0.2 molar equivalents of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.09–0.11 molar equivalents of pyridates. Even more preferably, step (a) involves the reaction of the polysaccharide with approximately 0.1 molar equivalents of pyridates. In one embodiment, the quenching agent is selected from adjacent diols, 1,2-amino alcohols, amino acids, glutathione, sulfite, bisulfite, dithionite, metabisulfite, thiosulfate, phosphite, hypophosphite or phosphoric acid. In one embodiment, the quenching agent is a 1,2-aminoalcohol of formula (I): (I) Where R1 is selected from H, methyl, ethyl, propyl or isopropyl. In one incarnation, the quenching agent is selected from sodium and potassium salts of sulfite, bisulfite, dithionite, metabisulfite, thiosulfate, phosphite, hypophosphite or phosphoric acid. In one incarnation, the quenching agent is an amino acid. In such incarnations, the amino acid in question could be chosen from serine, threonine, cysteine, cysteine, methionine, proline, hydroxyproline, tryptophan, tyrosine, or histidine. In one of the incarnations, the quenching agent is a sulfite such as bisulfite, dithionite, metabisulfite, thiosulfate. In one embodiment, the quenching agent is a compound containing two adjacent hydroxyl groups (adjacent diols), i.e., two hydroxyl groups covalently bonded to two adjacent carbon atoms. Ideally, the quenching agent should be a compound of the formula (II): (II) R1 and R2 are selected independently from H, methyl, ethyl, propyl or isopropyl. In a preferred formulation, the quenching agent is glycerol, ethylene glycol, propane-2,1-diol, butane-2,1-diol, or butane-3,2-diol, or ascorbic acid. In another preferred formulation, the quenching agent is butane-3,2-diol. In a preferred embodiment, the isolated serotype 35B polysaccharide is activated by a process that includes the step: (a) Reaction of the isolated serotype 35B polysaccharide with pyridates; (b) Quenching the oxidation reaction by adding butane-3,2-diol resulting from an activated serotype 35B polysaccharide. Following the oxidation step of the polysaccharide, it is noted that the polysaccharide is activated and referred to as the "activated polysaccharide" below. In one incarnation, the serotype 35B activated polysaccharide of the present invention has a mean molecular weight (Mw) between 15 kDa and 100 kDa. In another incarnation, the mean molecular weight (Mw) ranges between 25 kDa and 50 kDa. In a more preferred incarnation, the mean molecular weight (Mw) ranges between 30 kDa and 40 kDa. In one incarnation, the oxidation degree (also called "activation degree" in the current document) of the activated serotype 35B polysaccharide ranges between 2 and 20. In a preferred incarnation, the oxidation degree of the activated serotype 35B polysaccharide ranges between 4 and 15. In a more preferred incarnation, the oxidation degree of the activated serotype 35B polysaccharide is 9±3. In one incarnation, the activated serotype 35B polysaccharide and the carrier protein are lysed before step (b). Preferably, lysing occurs after step (a). In another incarnation, the activated polysaccharide is lysed after step (a), and the carrier protein is also lysed. In one embodiment, the activated serotype 35B polysaccharide is lysed after step (a) and the carrier protein is also lysed, and the activated polysaccharide and carrier protein are reconstituted in the same solution. In one incarnation, the activated serotype 35B polysaccharide and the carrier protein are independently lyzed (separate lysing). In another incarnation, the activated serotype 35B polysaccharide and the carrier protein are lyzed together (co-lysing). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is selected from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is sucrose. In one incarnation, the initial (wt) insertion ratio of activated serotype 35B capsular polysaccharide to carrier protein in step (b) ranges between 1:2 and 1:0.5. Ideally, the initial (wt) insertion ratio of activated serotype 35B capsular polysaccharide to carrier protein ranges between 1:1.2 and 1:0.6. Ideally, the initial (wt) insertion ratio of activated serotype 35B capsular polysaccharide to carrier protein ranges between 1:0.9 and 1:0.7. In one embodiment, the reduction reaction (C) is carried out in an aqueous solvent. Ideally, the reduction reaction (C) is carried out in a protonated solvent. In one embodiment, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). Preferably, reduction reaction (C) is carried out in the presence of dimethyl sulfoxide (DMSO). In one embodiment, the reduction reaction (c) is carried out in DMSO (dimethyl sulfoxide) solvent or in DMF (dimethyl sulfoxide). In a more preferred manner, the reduction reaction (c) is carried out in the solvent DMSO (dimethyl sulfoxide). In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium, or zinc borohydride in the presence of Bronsted or Lewis acids, such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In a preferred embodiment, the reducing agent is sodium cyanoborohydride. In one embodiment, between 0.2 and 5 molar equivalents of the reducing agent are used in step (c). Ideally, between 0.5 and 1.5 molar equivalents of the reducing agent are used in step (c). Even more ideally, between 0.9 and 1.1 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, there are unreacted aldehyde groups remaining in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. After conjugation with the carrier protein, the serotype 35B glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the serotype 35B glycoconjugate for the present invention includes a post-production purification step. 10.1 Invention-specific serotype 3 glycoconjugates of Streptococcus pneumoniae In one aspect, the invention relates to formulations containing a serotype 3 glycoconjugate of Streptococcus pneumoniae. The structure of the Streptococcus pneumoniae serotype 3 polysaccharide is well-known in the art of synthesis. The serotype 3 polysaccharide repeat unit consists of a linear disaccharide unit with one glucopyranose (Glcp) and one glucuronic acid (GlcpA) (see, for example, Geno K et al. (2015) Clin Microbiol Rev Vol 28:3, p 871-899). In one embodiment, the Streptococcus pneumoniae serotype 3 capsular polysaccharide used in the present invention is a synthetic carbohydrate. For example, a synthetic Streptococcus pneumoniae serotype 3 capsular polysaccharide can be prepared as described in WO2017178664 or WO2015040140. In a preferred embodiment, the source of bacterial polysaccharide under this invention may be serotype 3 Streptococcus pneumoniae bacteria. Bacterial strains that can be used as a source of serotype 3 Streptococcus pneumoniae polysaccharide may be obtained from selected culture kits (e.g., from a Streptococcus reference laboratory (Centers for Disease Control and Prevention, Atlanta, GA, USA)) or clinical models. Serotype 3 polysaccharides can be obtained directly from bacteria using isolation procedures familiar to a skilled industrialist (see, for example, the methods described in US2006 / 0228380, US2006 / 0228381, US2007 / 0184071, US2007 / 0184072, US2007 / 0231340, US2008 / 0102498, and WO2008 / 118752). They can also be synthesized using known synthetic protocols of a skilled industrialist. They can also be purchased (for example, from the American Agriculture Printing Group (ATCC, Manassas, VA, USA) (e.g., reference no. ATCC 172-X or ATCC 33-X)). If serotype 3 polysaccharides are obtained directly from bacteria, bacterial cells can be grown in a medium, preferably soy-based. After fermentation of the bacterial cells producing Streptococcus pneumoniae serotype 3 capsular polysaccharides, the bacterial cells can be lysed to produce cell lysate. The serotype 3 polysaccharides can then be isolated from the cell lysate using well-established purification techniques, including centrifugation, deep filtration, precipitation, ultrafiltration, activated carbon treatment, double filtration, and / or column chromatography (see, for example, US2006 / 0228380, US2006 / 0228381, and WO2008 / 118752). The purified serotype 3 capsular polysaccharides can then be used to prepare glycoconjugates. The capsular polysaccharide of serotype 3 isolated can be distinguished by purifying the serotype 3 polysaccharide from Streptococcus pneumoniae lysate and selectively sizing the purified polysaccharide using various parameters including, for example, molecular weight (Mw) mean weight. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). In one incarnation, the isolated serotype 3 capsular polysaccharide (i.e., purified before further processing) has an average molecular weight between 5 kDa and 5,000 kDa. In another incarnation, the isolated capsular polysaccharide has an average molecular weight between 100 kDa and 4,000 kDa. In a preferred incarnation, the isolated capsular polysaccharide has an average molecular weight between 1,000 kDa and 3,500 kDa. Ideally, to create serotype 3 conjugates with superior filtration, immunogenicity, and / or yield properties, the polysaccharide can be sized to a target molecular weight range prior to conjugation with a carrier protein. Beneficially, the size of the purified serotype 3 polysaccharide is reduced while preserving the essential features of polysaccharide construction. Mechanical or chemical sizing can be employed. In one incarnation, the volume of the purified serotype 3 polysaccharide is reduced by chemical hydrolysis. Chemical hydrolysis can be performed using a dilute acid (e.g., acetic acid, formic acid, propanoic acid). In one incarnation, chemical hydrolysis is performed using formic acid. In another, chemical hydrolysis is performed using propanoic acid. In a preferred incarnation, chemical hydrolysis is performed using acetic acid. Chemical hydrolysis can also be performed using a dilute strong acid (e.g., dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid, or dilute perchloric acid). In one incarnation, chemical hydrolysis is performed using dilute hydrochloric acid. In another, chemical hydrolysis is performed using dilute sulfuric acid. In yet another, chemical hydrolysis is performed using dilute phosphoric acid. In one embodiment, chemical hydrolysis is carried out using dilute nitric acid.In one of the incarnations, chemical hydrolysis is carried out using dilute perchloric acid. The size of purified serotype 3 polysaccharides can also be reduced by mechanical homogenization. In one application, the size of purified serotype 3 polysaccharides is reduced by high-pressure homogenization. High-pressure homogenization achieves high shear rates by pumping the process stream through a sufficiently small flow path. The shear rate increases with higher applied homogenization pressure, and the exposure time can be extended by recirculating the feed stream through the homogenizer. High-pressure homogenization can be a suitable process for reducing the size of purified serotype 3 polysaccharides while preserving the polysaccharide's structural characteristics. In one incarnation, the isolated serotype 3 capsular polysaccharide is scaled to an intermediate molecular weight between 5 kDa and 1000 kDa. In another incarnation, the isolated serotype 3 capsular polysaccharide is scaled to an intermediate molecular weight between 50 kDa and 300 kDa. In a preferred incarnation, the isolated serotype 3 capsular polysaccharide is scaled to an intermediate molecular weight between 100 kDa and 300 kDa. In one incarnation, the isolated serotype 3 capsular polysaccharide is scaled to an intermediate molecular weight between approximately 200 kDa and approximately 300 kDa. In one incarnation, the isolated serotype 3 capsular polysaccharide is scaled to an intermediate molecular weight between approximately 100 kDa and approximately 200 kDa. In one incarnation, the isolated serotype 3 capsular polysaccharide is not scaled. In one embodiment, the serotype 3 glycosurfactant of the present invention comprises a serotype 3 capsular polysaccharide with an average molecular weight (Mw) of said polysaccharide prior to conjugation ranging from 50 kDa to 1,000 kDa. Ideally, the average molecular weight (Mw) should be between 100 kDa and 300 kDa. The molecular weight (Mw) of the serotype 3 polysaccharide before conjugation refers to the molecular weight before activation of the serotype 3 polysaccharide (i.e., after a final sizing step but before the polysaccharide reacts with an activating agent). In the context of the present invention, the molecular weight of the serotype 3 polysaccharide is not substantially altered by the activation step, and the molecular weight of the serotype 3 polysaccharide included in the conjugate is similar to the molecular weight of the polysaccharide as measured before activation. In one embodiment, the serotype 3 glycosuric conjugate of the present invention includes a serotype 3 capsular polysaccharide where the molecular weight (Mw) of the said polysaccharide prior to conjugation ranges between 100 kDa and 200 kDa. In one embodiment, the serotype 3 glycosuric conjugate of the present invention includes a serotype 3 capsular polysaccharide where the molecular weight (Mw) of the said polysaccharide prior to conjugation ranges between 200 kDa and 300 kDa. In some incarnations, the invention's serotype 3 diabetic conjugate has a mean molecular weight (Mw) between 250 kDa and 20,000 kDa. In other incarnations, the serotype 3 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 15,000 kDa. In yet other incarnations, the serotype 3 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 10,000 kDa. Ideally, the serotype 3 diabetic conjugate has a mean molecular weight (Mw) between 500 kDa and 5,000 kDa. In one incarnation, the diabetic conjugate of serotype 3 has an average molecular weight (Mw) between 600 kDa and 3,000 kDa. The molecular weight of a polysaccharide can be measured by volumetric exclusion chromatography (SEC) combined with a multi-angle laser light scattering detector (MALLS). Another method for distinguishing the invention's serotype 3 glycoconjugates is by the number of lysine residues in the carrier protein (e.g., CRM197, DT, or SCP) that become conjugated with the polysaccharide, which can be distinguished as a range of conjugated lysine (the degree of conjugation). Evidence of lysine modification of the carrier protein, due to covalent bonds with the polysaccharide, can be obtained by amino acid analysis using routine methods familiar to those skilled in the art of synthesis. Conjugation reduces the number of recovered lysine residues compared to the carrier protein starter material used to create the conjugate material. In a preferred embodiment, the degree of conjugation of the invention's serotype 3 glycoconjugate ranges from 2 to 15. In a preferred incarnation, the degree of conjugation of the serotype 3 glycosurfactant of the invention ranges between 4 and 7. In some of these incarnations, the carrier protein is CRM197. In these other incarnations, the carrier protein is SCP. The serotype 3 glycoconjugates of the invention can also be distinguished by their (w / w) saccharide-to-carrier protein ratio. In some incarnations, the serotype 3 glycoconjugate-to-carrier protein ratio in the glycoconjugate (w / w) ranges from 0.5 to 3.0. In other incarnations, the saccharide-to-carrier protein ratio (w / w) ranges from 0.5 to 1.5. In a preferred incarnation, the serotype 3 glycoconjugate-to-carrier protein ratio ranges from 0.9 to 1.1. The invention's serotype 3 glycoconjugates can also be distinguished by the number of covalent bonds between the carrier protein and the polysaccharide as a function of the polysaccharide repeat units. In one incarnation, the invention's serotype 3 glycoconjugate includes at least one covalent bond between the carrier protein and the polysaccharide for every 4 polysaccharide repeat units. In another incarnation, the covalent bond between the carrier protein and the polysaccharide occurs at least once every 10 polysaccharide repeat units. In yet another incarnation, the covalent bond between the carrier protein and the polysaccharide occurs at least once every 15 polysaccharide repeat units. In a further incarnation, the covalent bond between the carrier protein and the polysaccharide occurs at least once every 25 polysaccharide repeat units. In further embodiment, the covalent bond between the carrier protein and the polysaccharide occurs at least once in every 50 polysaccharide repeat units of the polysaccharide.In an additional embodiment as well, the covalent bond between the carrier protein and the polysaccharide occurs at least once in every 100 polysaccharide repeat units of the polysaccharide. In other incarnations, the invention's serotype 3 glycoconjugate includes at least one covalent bond between the carrier protein and the polysaccharide for every 5 to 10 polysaccharide repeat units. In other incarnations, the invention's serotype 3 glycoconjugate includes at least one covalent linkage between the carrier protein and the polysaccharide for every 10 to 20 polysaccharide repeat units. In some incarnations, the carrier protein is CRM197, and the covalent bond between CRM197 and the polysaccharide occurs at least once every 4, 10, 15, or 25 polysaccharide repeats. In other incarnations, the carrier protein is SCP, and the covalent bond between SCP and the polysaccharide occurs at least once every 4, 10, 15, or 25 polysaccharide repeats. Serotype 3 glycoconjugates and invention-specific immunomodulatory constructs may contain a free polysaccharide that is not covalently conjugated to the carrier protein but is instead present within the glycoconjugate structure. The free polysaccharide may be non-covalently bound to the glycoconjugate (i.e., non-covalently attached to, adsorbed to, or interbedded with it). In a preferred incarnation, the serotype 3 diabetic conjugate includes less than approximately 50% of the free serotype 3 polysaccharides compared to the total amount of serotype 3 polysaccharides. In a preferred incarnation, the serotype 3 diabetic conjugate includes less than approximately 40% of the free serotype 3 polysaccharides compared to the total amount of serotype 3 polysaccharides. Also in a preferred incarnation, the serotype 3 diabetic conjugate includes less than approximately 25% of the free serotype 3 polysaccharides compared to the total amount of serotype 3 polysaccharides. Also in a preferred incarnation, the serotype 3 diabetic conjugate includes less than approximately 20% of the free serotype 3 polysaccharides compared to the total amount of serotype 3 polysaccharides. Also in a preferred incarnation, the serotype 3 diabetic conjugate includes less than approximately 15% Of free serotype 3 polysaccharides compared to the total amount of serotype 3 polysaccharides. Glycoconuts of serotype 3 can also be distinguished by their molecular size distribution (Kd). Volumetric exclusion chromatography (CL-4B) media can be used to determine the relative molecular size distribution of the conjugate. Volumetric exclusion chromatography (SEC) is used in gravity-feed columns to determine the molecular size distribution of conjugates. Large molecules are excluded from the pores in the media and exit more rapidly than small molecules. Fraction collectors are used to collect the column output. The fractions are tested using colorimetry with a saccharide assay. To determine Kd, the columns are calibrated to create a fraction at which molecules are completely excluded (V0), (Kd = 0), and a fraction representing maximum survival (Vi), (Kd = 1). The fraction at which a specific sample characteristic (Ve) is reached is related to Kd by the expression Kd = (Ve - V0) / (Vi - V0). In a preferred embodiment, at least 30% of diabetic conjugates of serotype 3Kd have a CL-4B score less than or equal to 0.3. In a preferred embodiment, at least 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85% of diabetic conjugates of serotype 3Kd have a CL-4B score less than or equal to 0.3. In a preferred embodiment, at least 60% of diabetic conjugates of serotype 3Kd have a CL-4B score less than or equal to 0.3. In a preferred embodiment, between 50% and 80% of diabetic conjugates of serotype 3Kd have a CL-4B score less than or equal to 0.3. In a preferred embodiment, between 65% and 80% of diabetic conjugates of serotype 3Kd have a CL-4B column less than or equal to 0.3. In one incarnation, the serotype 3 glycoconjugates of the present invention are prepared using amine reduction chemistry (see WO2006110381, WO2008143709, PCT / IB2022 / 054920). According to the present invention, the amine reduction group involves two steps: (1) oxidation (activation) of a purified saccharide, and (2) reduction of the activated saccharide and a carrier protein (e.g., CRM197, TT, or SCP) to form a glycoconjugate. As mentioned above, prior to oxidation, the polysaccharide can be sized to a target molecular weight (MW) range. Therefore, in one embodiment, the isolated polysaccharide is sized prior to oxidation. In one embodiment, the isolated polysaccharide is scaled to any target molecular weight (MW) range as defined above. In one embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to a carrier protein through a process that includes the step: (a) The isolated polysaccharide mentioned reacts with an oxidizing agent; (b) Synthesis of the activated polysaccharide from step (a) with a carrier protein; and (c) The activated polysaccharide complex and the carrier protein react with a reducing agent to form a glycoconjugate. After the oxidation step (a), it is noted that the saccharide is activated and referred to as the "activated polysaccharide". In one embodiment, the oxidizing agent is any agent that oxidizes a terminal hydroxyl group to an aldehyde. In another embodiment, the oxidizing agent is a pyrodate. For the purpose of the present invention, the term "pyrodate" includes both pyrodate and pyrodic acid; the term also includes metapyrodate (IO4-), orthopyrodate (IO65-), and various salts of pyrodate (for example, sodium pyrodate and potassium pyrodate). In one embodiment, the oxidizing agent is a pyrodate in the presence of divalent cations (see WO2008 / 143709). In one incarnation, the oxidizing agent is pyridic acid. In another incarnation, the oxidizing agent is pyridic acid in the presence of divalent cations. In yet another incarnation, the oxidizing agent is pyridic acid in the presence of Mg2+. In another incarnation, the oxidizing agent is pyridic acid in the presence of Ca2+. In another incarnation, the oxidizing agent is orthopyridates. In one incarnation, the oxidizing agent is sodium pyrodate. In another incarnation, the pyrodate used for oxidation is metapyrodate. In yet another incarnation, the pyrodate used for oxidation is sodium metapyrodate. When a polysaccharide reacts with pyridates, the pyridates oxidize adjacent hydroxyl groups to form carbonyl or aldehyde groups and cause the CC bond to cleavage. For this reason, the term "polysaccharide reaction with pyridates" includes the oxidation of adjacent hydroxyl groups by pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.01–2 molar equivalents of pyridates. Preferably, step (a) involves the reaction of the polysaccharide with 0.5–2 molar equivalents of pyridates. In one embodiment, step (a) involves the reaction of the polysaccharide with 0.01–2 molar equivalents of pyridic acid. Preferably, step (a) involves the reaction of the polysaccharide with 0.2–2 molar equivalents of pyridic acid. In a preferred embodiment, the degree of oxidation (also called the "activation degree" in the current document) of the activated serotype 3 polysaccharide ranges between 2 and 30. In a preferred embodiment, the degree of oxidation of the activated serotype 3 polysaccharide ranges between 2 and 20. In one incarnation, the oxidation degree of the activated serous type 3 polysaccharide ranges from 2 to 8. In one incarnation, the oxidation degree of the activated serous type 3 polysaccharide ranges from 11 to 19. In one incarnation, the activated polysaccharide and carrier protein are lyophilized before step (b). Ideally, lyophilization occurs after step (a). In another incarnation, the activated polysaccharide is lyophilized after step (a), and the carrier protein is also lyophilized. In one embodiment, the activated polysaccharide is lysed after step (a) and the carrier protein is also lysed. The activated polysaccharide and carrier protein are reconstituted in the same solution, and this synthesizes the activated polysaccharide and carrier protein together. In one incarnation, the activated polysaccharide and the carrier protein are lyophilized independently (separate lyophilization). In another incarnation, the activated polysaccharide and the carrier protein are lyophilized together (co-lyophilization). In one incarnation, lytication occurs in the presence of a non-reducing sugar. Possible non-reducing sugars include sucrose, trehalose, raffinose, stachyose, melisitose, dextran, mannitol, lactitol, and palatinate. In another incarnation, the sugar is chosen from a group consisting of sucrose, trehalose, and mannitol. In yet another incarnation, the sugar is sucrose, trehalose, or mannitol. In another incarnation, the sugar is trehalose. In yet another incarnation, the sugar is sucrose. In one incarnation, the initial input ratio (wt) of the serotype 3 activated capsular polysaccharide to the carrier protein in step (b) ranges between 1:4 and 1:0.1. In another incarnation, the initial input ratio (wt) of the serotype 3 activated capsular polysaccharide to the carrier protein ranges between 1:2 and 1:0.4. In one of the incarnations, the reduction reaction (C) is carried out in an aqueous solvent. In one embodiment, the reduction reaction (C) is carried out in a laprotonized solvent. In another embodiment, the reduction reaction (C) is carried out in a DMSO (dimethyl sulfoxide) solvent. In one embodiment, the reducing agent is sodium cyanoborohydride, sodium triacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, amine boranates such as pyridineborane, 2-picolineborane, 2,6-diborane-methanol, dimethylamine-borane, t-BuMeiPrN-BH, benzylamine-BH3, or 5-ethyl-2-methylpyridineborane (PEMB). In another embodiment, the reducing agent is sodium triacetoxyborohydride. In yet another embodiment, the reducing agent is sodium cyanoborohydride. In another embodiment, the reducing agent is sodium cyanoborohydride in the presence of nickel (see WO2018144439). In one embodiment, between 0.2 and 20 molar equivalents of the reducing agent are used in step (c). In another embodiment, between 0.5 and 3 molar equivalents of the reducing agent are used in step (c). At the end of the reduction reaction, unreacted aldehyde groups may remain in the conjugates, which can be covered using a suitable covering agent. In one embodiment, this covering agent is sodium borohydride (NaBH4). In one formulation, coating is achieved by mixing the product from step (c) with 1 to 20 molar equivalents of sodium borohydride. In another formulation, coating is achieved by mixing the product from step (c) with 1 to 3 molar equivalents of sodium borohydride. In one embodiment, the glycoconjugate for the present invention is prepared using CDI and / or CDT chemistry (see PCT / IB2022 / 054920). The chemistry of CDI and / or CDT involves two steps: (1) the reaction of the isolated polysaccharide with CDI and / or CDT in a protonated solvent to produce an activated polysaccharide (activation), and (2) the reaction of the activated polysaccharide with a carrier protein (e.g., CRM197 or SCP) to form a glycoconjugate. In one incarnation, the activating factor from step (1) is 1,1ˊ-carbonyldiimidazole (CDI). In another incarnation, the activating factor from step (1) is 1,1ˊ-carbonyl-di-(4,2,1-triazole) (CDT). In one embodiment, the isolated serotype 3 capsular polysaccharide is conjugated to a carrier protein by a process that includes the step: (a) The isolated polysaccharide mentioned reacts with CDI and / or CDT in a protonated solvent; (b) The activated polysaccharide from step (a) reacts with a carrier protein in a protonated solvent to form a glycoconjugate. In one incarnation, the serotype 3 glycoconjugates of the present invention are prepared using taplet chemistry (see e.g. PCT / IB2022 / 054914). According to the present invention, the tap chemistry involves three steps: (a) reaction of an isolated serous-type 3-capsular polysaccharide with a carbonic acid derivative and an azido linker in a protonated solvent to produce an activated azido polysaccharide (polysaccharide activation); (b) reaction of a carrier protein with an agent containing an N-hydroxysuccinimide (NHS) cleavage and an alkene group, where the NHS cleavage reacts with the amino groups to form an amide connection, thereby obtaining an alkene-associated carrier protein (carrier protein activation); (c) reaction of the activated azido polysaccharide from step (a) with the carrier protein from the activated alkene from step (b) by a Cu+1-mediated cyclic addition reaction of the alkene and the azido to form a glycoconjugate. After step (a), it is noted that the polysaccharide is activated and is referred to here as "the activated polysaccharide" or "the activated azido polysaccharide". After step (b), it is noted that the carrier is activated and referred to as the "activated carrier". As mentioned above, prior to activation (a), the polysaccharide can be scaled to a target molecular weight (MW) range. Therefore, in one embodiment, the isolated polysaccharide is sized prior to activation with a carbonic acid derivative and an azido linker. In one embodiment, the isolated polysaccharide is scaled to any target molecular weight (MW) range specified above. In one of its incarnations, the carbonic acid derivative in question is 1,1ˊ-carbonyldiimidazole (CDI) or 1,1ˊ-carbonyl-di-(4,2,1-triazole) (CDT). Preferably, the carbonic acid derivative in question is 1,1ˊ-carbonyldiimidazole (CDI). In one of the incarnations, the aforementioned azido link is a compound of the formula (I), (I) Where X is selected from the group consisting of CH2(CH2)n, (CH2CH2O)mCH2CH2, NHCO(CH2)n, NHCO(CH2CH2O)mCH2CH2, OCH2(CH2)n and O(CH2CH2O)mCH2CH2; where n is selected from 1 to 10 and m is selected from 1 to 4. In one of the incarnations, the aforementioned azido link is a compound of the formula (II), (II) In one of the incarnations, the aforementioned azido linker is 3-azido-propylamine. In one incarnation, the aforementioned agent containing an N-hydroxysuccinimide (NHS) moiety and an alkene group is an agent containing an N-hydroxysuccinimide (NHS) moiety and a terminal alkene. In one incarnation, the aforementioned agent containing an N-hydroxysuccinimide (NHS) moiety and an alkene group is an agent containing an N-hydroxysuccinimide (NHS) moiety and a cycloalkyne. In one of the incarnations, the aforementioned agent containing an N-hydroxysuccinimide (NHS) moiety and an alkene group is a compound of the formula (III). (III) Where X is selected from the set consisting of CH2O(CH2)nCH2C=O and CH2O(CH2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to 4. In one of its incarnations, the aforementioned agent containing an N-hydroxysuccinimide (NHS) moiety and an alkene group is a compound of the formula (IV): (IV) In one embodiment, step (a) involves the reaction of a polysaccharide with a carbonic acid derivative followed by the reaction of the carbonic acid derivative-activated polysaccharide with an azido binder in a protonated solvent to produce an activated azido polysaccharide. In one embodiment, in step (a), the isolated polysaccharide reacts with a carbonic acid derivative in a protonated solvent. In a preferred embodiment, the isolated polysaccharide reacts with a carbonic acid derivative in a solution consisting mainly of dimethyl sulfoxide (DMSO). In one preferred embodiment, the isolated polysaccharide reacts with CDI in dimethyl sulfoxide (DMSO). In another embodiment, the isolated polysaccharide reacts with CDI in anhydrous DMSO. Once the polysaccharide reacts with the carbonic acid derivative, and after the carbonic acid derivative has been finally quenched with water, the polysaccharide activated by the carbonic acid derivative reacts with an azido linker. In one embodiment, step (a) additionally involves the reaction of the activated polysaccharide with a carbonic acid derivative containing an amount of azido linker ranging from 0.01-10 molar equivalents to an amount of polysaccharide repeat unit of the activated polysaccharide (molar equivalents of RU). In one embodiment, the conjugation reaction (C) is carried out in an aqueous buffer. In another embodiment, the conjugation reaction (C) is carried out in an aqueous buffer with copper(I) as a catalyst. In yet another embodiment, the conjugation reaction (C) is carried out in an aqueous buffer with an oxidant and copper(I) as a catalyst. In a preferred embodiment, the conjugation reaction (C) is carried out in an aqueous buffer with copper(I) as a catalyst and ascorbate as an oxidant. In one embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine can also be added to protect the protein from side reactions. Therefore, in a preferred embodiment, the conjugation reaction (C) is carried out in an aqueous buffer in the presence of copper(I) as a catalyst and ascorbate as an oxidizing agent, with the reaction mixture also including THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine. After the nibble coupling reaction, unreacted azido groups may remain in the conjugates, which can be covered by a suitable azido covering agent. Therefore, in one embodiment, after step (c), the unreacted azido groups present in the conjugates are covered by a suitable azido covering agent. In one embodiment, this azido covering agent is an agent containing an alkene group. In another embodiment, this azido covering agent is an agent containing a terminal alkene. In yet another embodiment, this azido covering agent is an agent containing a cycloalkene. In one of the incarnations, the aforementioned azido group covering factor is a compound of the formula (V), (V) Where X is (CH2)n and where n is selected from 1 to 15. In one incarnation, this azido group covering agent is a propargyl alcohol. Therefore, in one incarnation, after step (c), the process also includes a step to cover the non-reactive azido groups present in the conjugates with an azido group covering agent. Following the nicotinic coupling reaction, unreacted alkene groups may remain in the conjugates; these can be covered by a suitable alkene covering agent. In one embodiment, this alkene covering agent is an azido-containing agent. In one of the incarnations, the covering agent for the alkene group mentioned is a compound of the formula (VI), (VI) Where X is (CH2)n, where n is selected from 1 to 15. In one of the incarnations, this alkene group covering agent is 3-azido-1-propanol. Therefore, in one embodiment, after step (c) the process also includes a step of covering the remaining unreacted alkene groups in the conjugates using an alkene group covering agent. After conjugation with the carrier protein, the glycoconjugate can be purified (enriched with respect to the amount of saccharide-protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the glycoconjugate for the present invention includes a purification step after production. In one respect, the invention's serotype 3 glycoconjugate is produced according to the chemistry described above and in application PCT / IB2022 / 054914, which is incorporated into the reference as a whole. Therefore, in one embodiment, the invention's serotype 3 glycoconjugate comprises a serotype 3 polysaccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII): (VII), Where X is selected from the group consisting of CH2(CH2)n', (CH2CH2O)mCH2CH2, NHCO(CH2)n', NHCO(CH2CH2O)mCH2CH2, OCH2(CH2)n' and O(CH2CH2O)mCH2CH2; where n' is selected from 1 to 10 and m is selected from 1 to 4, Where X' is selected from the set consisting of CH2O(CH2)n''CH2C=O, CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. Formula (VII) is a schematic representation of the invention's serotype 3 glycoconjugates. It should not be understood that there is a bond present in every polysaccharide repeat unit. Instead, the majority of the pneumococcal serotype 3 polysaccharide repeat units remain unmodified, and the covalent bonds between the carrier protein and the polysaccharide are present for the majority of the polysaccharide repeat units. In addition, a single carrier protein (CP) molecule can bind to more than one pneumococcal serotype 3 polysaccharide molecule, and a single pneumococcal serotype 3 polysaccharide molecule can bind to more than one single carrier protein (CP) molecule. In a preferred embodiment, the invention's serotype 3 glycoconjugate comprises a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is CH2(CH2)n', where n' is equal to 2, and where X' is CH2O(CH2)n''CH2C=O where n' is equal to 1. In one incarnation, the invention's serotype 3 glycoconjugate comprises a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is CH2(CH2)n', where n' is selected from 1 to 10, and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one incarnation, n' is selected from 1 to 5 and n'' from 0 to 10. In another incarnation, n' is selected from 1 to 5 and n'' from 0 to 5. In yet another incarnation, n' is selected from 1 to 3 and n'' from 0 to 3. In another incarnation, n' is selected from 1 to 2 and n'' from 0 to 2. In a specific incarnation, n' equals 1 and n' equals 0. In another incarnation, n' equals 2 and n' equals 0. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is CH2(CH2)n', where n' is selected from 1 to 10 and where CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is (CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one embodiment, m is selected from 1 to 3 and n'' is selected from 0 to 10. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is (CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is NHCO(CH2)n', where n' is selected from 1 to 10 and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is NHCO(CH2)n', where n' is selected from 1 to 10 and where X' is CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is NHCO(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one embodiment, m is selected from 1 to 3 and n'' is selected from 0 to 10. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is NHCO(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is OCH2(CH2)n', where n' is selected from 1 to 10 and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is OCH2(CH2)n', where n' is selected from 1 to 10 and where X' is CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is O(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2)n''CH2C=O, where n'' is selected from 0 to 10. In one embodiment, the invention's serotype 3 glycoconjugate includes a serotype 3 saccharide covalently conjugated to a carrier protein (CP) via a spacer and has the general formula (VII), where X is O(CH2CH2O)mCH2CH2, where m is selected from 1 to 4 and where X' is CH2O(CH2CH2O)m'(CH2)n''CH2C=O, where n'' is selected from 0 to 10 and m' is selected from 0 to 4. After conjugation with the carrier protein, the serotype 3 glycoconjugate can be purified (enriched with respect to the amount of saccharide and protein conjugate) by a variety of techniques familiar to a skilled person. These techniques include dialysis, binary concentration / filtration, tangential flow filtration / precipitation, column chromatography (DEAE or hydrophobic interfacial chromatography), and deep filtration. Therefore, in one embodiment, the production process of the glycoconjugate for the present invention includes a purification step after production. 11.1 Carrier proteins The glycoconjugate component is a carrier protein to which the pneumococcal polysaccharide is conjugated. The terms "carrier protein," "carrier protein," or "carrier" can be used interchangeably here. Carrier proteins must be subject to standard conjugation procedures. In a preferred embodiment, the pneumococcal glycosuric conjugate protein is selected from a pool consisting of: DT (diphtheria toxoid), TT (tetanus toxoid) or a C-fraction of TT, CRM197 (a non-toxic but antigenically identical variant of diphtheria toxoid), other DT mutants (e.g., CRM176, CRM228, CRM45 (Uchida et al. (1973) J. Biol. Chem. 218:3838-3844), CRM9, CRM102, CRM103, or CRM107; and other mutations described by Nicholls and Youle in Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc. (1992); and Glu-148 deletion or mutation to Asp, Gln, or Sero and / or Ala. 158 to GIy and other mutations described in U.S. Patent Nos. 4,709,017 and 4,950,740; a mutation of at least one or more Lys 516, Lys 526, Phe 530 and / or Lys 534 and other mutations detected in U.S. Patent Nos. 5,917,017 and 6,455,673; or a fragment detected in U.S. Patent No. 5,843,711, pneumococcal pneumolysin(ply) (Kuo et al.).(1995) Infect lmmun 63:2706-2713) including ply detoxified in some manner, e.g., dPLY-GMBS (WO 2004 / 081515, WO 2006 / 032499) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD, PhtE (PhtA, PhtB, PhtD or PhtE sequences are detected in WO 00 / 37105 and WO 00 / 39299) and Pht protein fusions, e.g., PhtDE fusions, PhtBE fusions, Pht AE fusions (WO 01 / 98334, WO 03 / 054007, WO 2009 / 000826), OMPC (meningococcal outer membrane protein), where Typically extracted from the Neisseria meningitidis serogroup B (EP0372501), PorB (from Neisseria meningitidis), PD (Haemophilus influenzae type b protein; see, for example, EP0594610 B), or immunologically functional equivalents thereof, synthetic peptides (EP0378881, EP0427347), heat shock proteins (WO 93 / 17712, WO 94 / 03208), pertussis proteins (WO 98 / 58668, EP0471177), cytokines, lymphokines, hormones or growth factors (WO 91 / 01146), synthetic proteins including multiple human CD4+ T-cell epitopes of various antigens derived from a pathogen (Falugi et al.).(2001) Eur J Immunol 31:3816-3824) e.g., protein N19 (Baraldoi et al. (2004) Infect lmmun 72:4884-4887), pneumococcal surface protein PspA (WO 02 / 091998), iron uptake proteins (WO 01 / 72337), Clostridium difficile toxin A or B (WO 00 / 61761), transferrin binding proteins, pneumococcal adhesion protein (PsaA), synthetic Pseudomonas aeruginosa exotoxin A (specifically non-toxic mutant forms of it) (e.g., exotoxin A carrying a substitution at glutamic acid 553) (Douglas et al. (1987) J. (Bacteriol. 169(11):4967-4971). Other proteins, such as ovarian albumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), or purified protein derivative (PPD) of tuberculin, can also be used as carrier proteins. Other suitable carrier proteins include inactive bacterial toxins, such as cholera toxoid (e.g., as described in WO 2004 / 083251), Escherichia coli LT, E. coli ST, and Pseudomonas aeruginosa exotoxin A.Another suitable carrier protein is Streptococcal C5a peptidase (SCP). Other suitable carrier proteins include Rizafidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785](CP1)(WO2020056202). In a preferred embodiment, the invention's pneumococcal glycosuric conjugate protein is selected from the pool of TT, DT, DT mutants (e.g., CRM197), and Streptococcus pneumoniae C5a peptidase (SCP). In one incarnation, the pneumococcal glycosurfactant carrier protein is DT (diphtheria toxoid). In another incarnation, the pneumococcal glycosurfactant carrier protein is TT (tetanus toxoid). In another incarnation, the protein carrying the pneumococcal glycosuric conjugate is PD (the D protein of Haemophilus influenzae; see, for example, EP0594610 B). In a preferred embodiment, the protein carrying the pneumococcal polysaccharide conjugate is CRM197 or Streptococcus pneumoniae C5a peptidase (SCP). In another incarnation, the protein carrying the pneumococcal glycosuric conjugate is rizafidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785](CP1). In a preferred embodiment, some or all of the glycosylated pneumococci of the present invention conjugate to the CRM197 protein. The CRM197 protein is a non-toxic form of diphtheria toxoid but is immunologically indistinguishable from diphtheria toxoid. CRM197 is produced by infectious Corynebacterium diphtheria via phagocytosis of the non-toxin-producing β197tox-synthesized β197toxin, which is synthesized by a nitrosoguanidine mutation of the toxin-producing corynephage beta-bacterium (Uchida et al. (1971) Nature New Biology 233:8-11). The CRM197 protein has the same molecular weight as diphtheria toxoid but is distinguished by a single base change (guanine to adenine) in the structural gene. This single-base change causes the substitution of an amino acid (glutamic acid for glycine) in the mature protein and removes the toxic properties of diphtheria toxin. The CRM197 protein is a T-cell-dependent carrier that is efficient and safe for polysaccharides. Further details regarding CRM197 and its production can be found, for example, in U.S. Patent No. 5,614,382. In one incarnation, some or all of the pneumococcal glycosides of the present invention are associated with the CRM197 protein. In another incarnation, some or all of the pneumococcal glycosides of the present incarnation are associated with the CRM197 protein or the A-strand of CRM197 (see CN103495161). In yet another incarnation, some or all of the pneumococcal glycosides of the present incarnation are associated with the A-strand of CRM197 produced by recombinant Escherichia coli (see CN103495161). In other preferred incarnations, the protein carrying part or all of the pneumococcal glycoconjugates of the present invention is SCP (pneumococcal C5a peptidase). See WO2022249106, specifically pages 95–111, which are incorporated into the reference. In one incarnation, the pneumococcal glycosurfactant carrier protein of the invention is SCP of GBS (SCPB). An example of SCPB is provided in sequence ID 3 of WO97 / 26008. See also sequence ID 3 of WO00 / 34487. In other preferred incarnations, the invention's pneumococcal glycosurfactant carrier protein is SCP of GAS (SCPA). SCPA examples can be found in sequence IDs 1 and 2 of WO97 / 26008. See also sequence IDs 1, 2 and 23 of WO00 / 34487. In a preferred embodiment, the invention's pneumococcal glycosurfactant carrier protein is an enzymatically inactive SCP. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is a fragment of SCP. In another embodiment, the pneumococcal glycosurfactant carrier protein of the invention is a fragment of SCPA. Preferably, the pneumococcal glycosurfactant carrier protein of the invention is a fragment of SCPB. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is a fragment of SCP that includes the protease domain, the protease-associated domain (PA domain) and three fibronectin III (Fn) domains, but does not include a pre-export signaling sequence, a support sequence, and a cell wall stabilization domain. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is a fragment of SCP that includes the protease domain, the protease-associated domain (PA domain) and three fibronectin III (Fn) domains, but does not include a pre-export signaling sequence, a support sequence, and a cell wall stabilization domain. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an inactive fragment of SCP that includes the protease domain, the protease-associated domain (PA domain) and two of the three fibronectin III (Fn) domains, but does not include the pre-export signaling sequence, the support sequence, and the cell wall stabilization domain. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCP. In another embodiment, the enzymatically inactive fragment of SCP includes the protease domain, the protease-associated domain (PA domain), and two of the three fibronectin III (Fn) domains, but does not include the pre-export signaling sequence, the pro-reinforcement sequence, or the cell wall stabilization domain. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCPA. In another embodiment, the enzymatically inactive fragment of SCPA includes a protease domain, a protease-associated domain (PA domain), and three fibronectin III (Fn) domains, but does not include a pre-export signaling sequence, a pro-reinforcement sequence, or a cell wall stabilization domain. In a preferred embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCPB. Preferably, the enzymatically inactive fragment of SCPB includes the protease domain, the protease-associated domain (PA domain), and three fibronectin III (Fn) domains, but excludes the pre-export signaling sequence, the pro-reinforcement sequence, and the cell wall stabilization domain. In one incarnation, the enzymatic activity of SCP is quenched by the substitution of at least one amino acid from the wild-type sequence. In another incarnation, this substitution is selected from the group consisting of D130A, H193A, N295A, and S512A. The numbers indicate the lagging position of the peptidase according to sequence ID number 1 of WO00 / 34487. Therefore, in one incarnation, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCP, where the aforementioned quenching is achieved by the substitution of at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one incarnation, the substitution should be at least one amino acid in the first part of the protease domain. In another incarnation, the substitution should be at least one amino acid in the second part of the protease domain. In one incarnation, the substitution should be selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation, the substitution should be D130A. In another, it should be H193A. In yet another, it should be N295A. And in yet another, it should be S512A. In one incarnation, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCPA, where the aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one incarnation, the substitution should be at least one amino acid in the first part of the protease domain. In another incarnation, the substitution should be at least one amino acid in the second part of the protease domain. In one incarnation, the substitution should be selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation, the substitution should be D130A. In another, it should be H193A. In yet another, it should be N295A. And in yet another, it should be S512A. In one incarnation, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCPB, where the aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one incarnation, the substitution should be at least one amino acid in the first part of the protease domain. In another incarnation, the substitution should be at least one amino acid in the second part of the protease domain. In one incarnation, the substitution should be selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation, the substitution should be D130A. In another, it should be H193A. In yet another, it should be N295A. And in yet another, it should be S512A. In one incarnation, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCP, where the aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one incarnation, the substitution should be at least one amino acid in the first part of the protease domain. In another incarnation, the substitution should be at least one amino acid in the second part of the protease domain. In one incarnation, the substitution should be selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation, the substitution should be D130A. In another, it should be H193A. In yet another, it should be N295A. And in yet another, it should be S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCP comprising the protease domain, the protease-binding domain (PA domain), and three fibronectin III (Fn) domains, but excluding the pre-export signaling sequence, the pro-regulatory sequence, and the cell wall stabilization domain. The aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one embodiment, this substitution is at least one amino acid in the first part of the protease domain. In another embodiment, this substitution is at least one amino acid in the second part of the protease domain. In one embodiment, this substitution is selected from the group of D130A, H193A, N295A, and S512A. In one embodiment, this substitution is D130A. In another incarnation, the replacement mentioned is H193A. In another incarnation, the replacement mentioned is N295A. And in yet another incarnation, the replacement mentioned is S512A.In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCPA comprising the protease domain, the protease-binding domain (PA domain), and three fibronectin III (Fn) domains, but excluding the pre-export signaling sequence, the pro-regulatory sequence, and the cell wall stabilization domain. The aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one embodiment, this substitution is at least one amino acid in the first part of the protease domain. In another embodiment, this substitution is at least one amino acid in the second part of the protease domain. In one embodiment, this substitution is selected from the group of D130A, H193A, N295A, and S512A. In one embodiment, this substitution is D130A. In another incarnation, the replacement mentioned is H193A. In another incarnation, the replacement mentioned is N295A. And in yet another incarnation, the replacement mentioned is S512A.In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCPB comprising the protease domain, the protease-binding domain (PA domain), and three fibronectin III (Fn) domains, but excluding the pre-export signaling sequence, the pro-regulatory sequence, and the cell wall stabilization domain. The aforementioned quenching is achieved by substituting at least one amino acid from the wild-type sequence. Ideally, this substitution should be at least one amino acid in the protease domain. In one embodiment, the substitution is at least one amino acid in the first part of the protease domain. In another embodiment, the substitution is at least one amino acid in the second part of the protease domain. In one embodiment, the substitution is selected from the group of D130A, H193A, N295A, and S512A. In one embodiment, the substitution is D130A. In another incarnation, the replacement mentioned is H193A. In another incarnation, the replacement mentioned is N295A. And in yet another incarnation, the replacement mentioned is S512A. In one incarnation, the enzymatic activity of SCP is inhibited by the substitution of at least two amino acids from the wild-type sequence. In one incarnation, at least two of the aforementioned amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation, at least two of the aforementioned amino acid substitutions are D130A and H193A. In another incarnation, at least two of the aforementioned amino acid substitutions are D130A and N295A. In yet another incarnation, at least two of the aforementioned amino acid substitutions are D130A and S512A. In another incarnation, at least two of the aforementioned amino acid substitutions are H193A and N295A. In one incarnation, at least two of the amino acid substitutions mentioned are H193A and S512A. In one incarnation, at least two of the amino acid substitutions mentioned are N295A and S512A. Therefore, in one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCP, where the aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Ideally, this substitution should be of at least two amino acids in the protease domain. In one embodiment, this substitution should be of at least two amino acids in the first part of the protease domain. In another embodiment, this substitution should be of at least two amino acids in the second part of the protease domain. In one embodiment, at least two of these amino acid substitutions should be selected from the group consisting of D130A, H193A, N295A, and S512A. In yet another embodiment, at least two of these amino acid substitutions should be D130A and H193A. In one incarnation, at least two of the listed amino acid substitutions are D130A and N295A. Ideally, at least two of the listed amino acid substitutions are D130A and S512A.In one incarnation, at least two of the listed amino acid substitutions are H193A and N295A. In another incarnation, at least two of the listed amino acid substitutions are H193A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are N295A and S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCPA, where the aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Ideally, this substitution should be of at least two amino acids in the protease domain. In one embodiment, this substitution should be of at least two amino acids in the first part of the protease domain. In another embodiment, this substitution should be of at least two amino acids in the second part of the protease domain. In one embodiment, at least two of the aforementioned amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, at least two of the aforementioned amino acid substitutions are D130A and H193A. In another embodiment, at least two of the aforementioned amino acid substitutions are D130A and N295A. Ideally, at least two of the amino acid substitutions mentioned should be D130A and S512A.In one incarnation, at least two of the listed amino acid substitutions are H193A and N295A. In another incarnation, at least two of the listed amino acid substitutions are H193A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are N295A and S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive SCPB, where the aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Ideally, this substitution should be of at least two amino acids in the protease domain. In one embodiment, this substitution should be of at least two amino acids in the first part of the protease domain. In another embodiment, this substitution should be of at least two amino acids in the second part of the protease domain. In one embodiment, at least two of the aforementioned amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, at least two of the aforementioned amino acid substitutions are D130A and H193A. In another embodiment, at least two of the aforementioned amino acid substitutions are D130A and N295A. Ideally, at least two of the amino acid substitutions mentioned should be D130A and S512A.In one incarnation, at least two of the listed amino acid substitutions are H193A and N295A. In another incarnation, at least two of the listed amino acid substitutions are H193A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are N295A and S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCP, where the aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Preferably, the aforementioned substitutions are at least two amino acids in the protease domain. In one embodiment, the aforementioned substitutions are at least two amino acids in the first part of the protease domain. In another embodiment, the aforementioned substitutions are at least two amino acids in the second part of the protease domain. In one embodiment, at least two of the aforementioned amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. In one embodiment, at least two of the aforementioned amino acid substitutions are D130A and H193A. Preferably, at least two of the aforementioned amino acid substitutions are D130A and N295A. In one incarnation, at least two of the amino acid substitutions mentioned are D130A and S512A.In one incarnation, at least two of the listed amino acid substitutions are H193A and N295A. In another incarnation, at least two of the listed amino acid substitutions are H193A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are N295A and S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCP comprising the protease domain, the protease-binding domain (PA domain), and three fibronectin III (Fn) domains, but excluding the pre-export signaling sequence, the pro-regulatory sequence, and the cell wall stabilization domain. The aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Ideally, this substitution should be of at least two amino acids in the protease domain. In one embodiment, this substitution is of at least two amino acids in the first part of the protease domain. In another embodiment, this substitution is of at least two amino acids in the second part of the protease domain. In yet another embodiment, at least two of these amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. Ideally, at least two of the amino acid substitutions mentioned should be D130A and H193A.In one incarnation, at least two of the listed amino acid substitutions are D130A and N295A. In another incarnation, at least two of the listed amino acid substitutions are D130A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are H193A and N295A. In yet another incarnation, at least two of the listed amino acid substitutions are H193A and S512A. In yet another incarnation, at least two of the listed amino acid substitutions are N295A and S512A. In one embodiment, the pneumococcal glycosurfactant carrier protein of the invention is an enzymatically inactive fragment of SCPA comprising the protease domain, the protease-binding domain (PA domain), and three fibronectin III (Fn) domains, but excluding the pre-export signaling sequence, the pro-regulatory sequence, and the cell wall stabilization domain. The aforementioned quenching is achieved by substituting at least two amino acids of the wild-type sequence. Ideally, this substitution should be of at least two amino acids in the protease domain. In one embodiment, this substitution is of at least two amino acids in the first part of the protease domain. In another embodiment, this substitution is of at least one amino acid in the second part of the protease domain. In yet another embodiment, at least two of these amino acid substitutions are selected from the group consisting of D130A, H193A, N295A, and S512A. In one incarnation...
Claims
1. An immunogenic formulation containing glycosides from different serotypes of Streptococcus pneumoniae and a lipid adjuvant containing saponins, including a liposome structure containing monophosphoryl lipid A (MPLA) and at least one saponin, where the liposome structure includes (1) a lipid bilayer containing phospholipids and (2) cholesterol.
2. An immunogenic formulation of protective element 1 where the saponin is QS-21.
3. An immunogenic formulation of either protective element 1 or 2 where the phospholipids are DMPC and DMPG.
4. The immunogenic formulation of protective element 1, where the saponin-containing lipid adjuvant includes monophosphoryl lipid A (MPLA), QS-21, DMPC, DMPG, and cholesterol in a phosphate buffer.
5. The immunogenic formulation of any of protective elements 1-4, where MPLA is monophosphoryl-3-decyl A.
6. The immunogenic formulation of any of protective elements 1-5, containing approximately 0.1 to approximately 1.0 mg / mL or more of MPLA.
7. The combination immunogenic from any of the protective elements 1-6 includes approximately 0.05 to approximately 1.0 mg / mL or more of QS-21.
8. The combination immunogenic from any of the protective elements 1-7 includes approximately 0.5 to approximately 20 mg / mL or more of cholesterol.
9. The combination immunogenic from any of the protective elements 1-8 includes approximately 0.5 to approximately 20 mg / mL or more of DMPC.
10. The combination immunogenic from any of the protective elements 1-9 includes approximately 0.5 to approximately 3.0 mg / mL or more of DMPG. 11- The immunogenic formulation of protective factor 1, where the saponin-containing lipid adjuvant mentioned includes monophosphoryl-3-decyl A at approximately 0.4 mg / mL, QS-21 at approximately 0.2 mg / mL, DMPC at approximately 14 mg / mL, DMPG at approximately 1.6 mg / mL, and cholesterol at approximately 11 mg / mL. 12- The immunogenic formulation of protective factor 1, where the saponin-containing lipid adjuvant mentioned includes monophosphoryl-3-decyl A at approximately 0.8 mg / mL, QS-21 at approximately 0.4 mg / mL, DMPC at approximately 28 mg / mL, DMPG at approximately 3.2 mg / mL, and cholesterol at approximately 22 mg / mL. 13- The immunogenic formulation of protective element 1, where the saponin-containing lipid adjuvant mentioned includes monophosphoryl-3-decyl A at approximately 0.2 mg / mL, QS-21 at approximately 0.1 mg / mL, DMPC at approximately 7 mg / mL, DMPG at approximately 0.8 mg / mL, and cholesterol at approximately 5.5 mg / mL. 14- The immunogenic formulation of any of the protective elements 1-13, where the saponin-containing lipid adjuvant mentioned is homologous.
15. The immunogenic combination of any of the protective elements 1-13, where the specified saponin-containing lipid adjuvant is heterozygous.
16. The immunogenic combination of any of the protective elements 1-15 includes at least 20 glycosylated conjugates from different serotypes of Streptococcus pneumoniae.17- The immunogenic composition of any of the protective elements 1-16 includes glycosidic conjugates of the Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 18- The immune composition of any of the protective elements 1-16 includes glycosidic conjugates of the Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. 19- The immunogenic combination of any of the protective elements 1-18 includes glycoconjugates of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B and additionally includes at least ten glycoconjugates of Streptococcus pneumoniae serotypes 2, 6C, 7C, 7F, 9N, 10B, 15C, 16F, 17F, 20A, 20B, 21, 22A, 24B, 27, 29, 31, 33B, 34, 35F, 38, 72, and 73. 20- The immunogenic formulation of protective element 19, which is a pneumococcal conjugate formulation with 35 valence. 21- The immunogenic formulation of any of protective elements 1 to 20 for use as a medicine.22- The immune-boosting formulation of any of the protective elements 1 to 20 for use as a vaccine.
